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Abstract
Cancer has been, and still remains, one of the most complicated diseases to treat. As a result of
the side effects experienced from current cancer treatment methods, there has been a growing
interest in the development of targeted drug delivery systems that can destroy cancer cells, but
render healthy tissue unharmed. To address this challenge, magnetite nanoaggregates were
synthesized through the precipitation of iron oxide in the presence of polymers, conjugated with
folic acid for folate targeting, and loaded with curcumin for cancer treatment. The resulting
magnetite nanoparticles were 10 – 20 nm in size and the aggregates formed varied in size
depending on the ratio of polymers present. Furthermore, the ratio of polymers on the particle
surfaces, in addition to the presence of folic acid, played a major role in sustaining curcumin
release. In vitro studies with MDA-MB-231 and MDA-MB-468 cells revealed that the particles
without curcumin exhibited low cytotoxicity up to 2 mg/mL in both cells lines. However, in the
presence of curcumin, toxicity to MDA-MB-468 cells was observed. In addition, folic acid
functionalized particles showed enhanced uptake in MDA-MB-468 cells, which express elevated
levels of the folic acid receptor, in comparison to non-targeted particles, suggesting the
possibility of selective delivery towards cancer cells.

Keywords
targeted cancer treatment, drug delivery, curcumin, folate receptor, magnetic nanoparticles,
controlled drug release
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Chapter 1
1

Introduction
1.1

Motivation and Cancer Treatment Overview

For years researchers have been seeking a means of solving one of the toughest puzzles in the
world; cancer. In 2013, there were approximately 1.6 million cases of cancer with 580,350
deaths occurring in the United States,1 and 187,600 cases of cancers in Canada, of which 75,500
cases resulted in death.2 Traditional treatment methods including one of, or a combination of,
surgery, radiation therapy, and chemotherapy have been enhanced overtime which is evident by
the high incidences of cured individuals. However, these treatment methods are still not flawless.
Surgery is invasive, bearing many risks to the patient before and after the procedure. Radiation
therapy involves both early side effects such as skin erythema, nausea, dryness, and itchiness,
and late effects which include long term conditions such as vascular or neural damage, atrophy,
and radiation-induced fibrosis.3 Both early and late side effects associated with radiation therapy
are local, being manifested in the tissue that was irradiated. This outlines the main difference
between radiation therapy and chemotherapy, as the latter causes systemic side effects
(throughout the entire human body). The anti-cancer agents used in chemotherapy destroy
rapidly dividing cells, whether cancerous or healthy. Therefore, there is a strong need for a
technology that can direct chemotherapeutic agents to the tumour site once administered, thereby
rendering healthy tissue unharmed.

1.2

Drug Delivery Systems (DDS) for Cancer Treatment

Today, many cancer awareness societies quote targeted therapy as one of the options of cancer
treatment. Indeed, there has been a plethora of research aimed at the development of drug
delivery systems (DDS) that can transport chemotherapeutics to the site of interest, thereby
localizing the drug and decreasing or potentially eliminating side effects. Common drug delivery
systems include liposomes, exosomes, micelles, dendrimers or different polymeric networks, and
nanoparticles, which encompass a wide variety of different systems.4
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1.2.1

Liposomes, Micelles, and Exosomes

Lipid-based systems such as liposomes and micelles have been used for drug delivery and cell
targeting due to their biocompatibility and ability to increase the bioavailability of many drugs.5
Sardan et al. synthesized peptide amphiphile (PA)-incorporating liposomes for cell targeting.6
Liposomes containing PA were made using a 7:8:1 ratio of 1, 2-dioleoyl-sn-glycero-3[phosphor-rac-(1-glycerol)] (DOPG), cholesterol (CHOL), and PA respectively using a
curvature tuned preparation method. The amphiphilic nature of the system allowed for the
incorporation of Rhodamine B and nile red as model hydrophilic and hydrophobic drugs,
respectively.
In other work, reduction-sensitive, shell-sheddable micelles synthesized using poly(ethylene
glycol)-poly(ε-caprolactone) (PEG-PCL) copolymers were used to encapsulate doxorubicin for
targeting of tumour cell nuclei.7 The authors reported more efficient release of doxorubicin
when using reduction-sensitive versus non-reduction-sensitive micelles. Exosomes—endocytotic
membrane vesicles excreted by many cells—are also used for drug encapsulation. Tian et al.
focused on the delivery of doxorubicin, but using exosomes as delivery vehicles.8 Exosomes
were obtained from immature dendritic cells (imDCs) of mice in order to reduce immunogenicity
and toxicity, and then functionalized to express a common exosomal membrane protein
(Lamp2b) conjugated to αv integrin iRGD peptide for tumour targeting.

1.2.2

Hydrogels

There has been extensive research involving hydrogels—materials composed of polymer chain
networks—for targeted cancer treatment and other biomedical applications,9-11 with recent
emphasis on “smart” hydrogels which are capable of changing their properties in response to
certain stimuli such as temperature and pH.12 Thermoresponsive poloxamer hydrogels
conjugated with linoleic acid-coupled Pluronic-F127 (Plu-CLA) were synthesized and loaded
with docetaxel for the treatment of metastatic gastric cancer.13 The hydrogels remained in
solution at room temperature for intraperitoneal injection, upon which gelation occurred at body
temperature. The gelation along with the coupled Plu-CLA was noted to achieve more sustained
release of docetaxel, with higher cancer cell destruction was reported for hydrogel-loaded
docetaxel than docetaxel alone.
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1.2.3

Dendrimers

Dendrimers may be one of the oldest known drug delivery systems, dating back to the late
1970’s, although their application as drug delivery vehicles or “host-guest” systems was not
described at the time.14 However, for the past decade there has been a strong focus on the use of
dendrimers as drug delivery systems for cancer treatment.15 Because dendrimers can be
synthesized to incorporate a wide variety of anti-cancer agents, and functionalized to include
various ligands capable of targeting cancer cell surface receptors, they make promising drug
delivery vehicles. Modi et al. synthesized fluorescein-labeled generation 5 (G5) PAMAM
dendrimers conjugated with FSH33 which is the binding domain of follicle stimulating hormone
(FSH).16 Due to the high affinity of FSH33 to the FSH receptor (FSHR) present on the surface of
ovarian cancer cells, the functionalized dendrimers showed significant uptake by ovarian cancer
cells resulting in the down-regulation of survivin (an anti-apoptotic protein) meanwhile
rendering normal non-FSHR expressing ovarian cells unharmed.

1.2.4

Nanoparticles

Several types of nanoparticles have been developed using a wide variety of different materials
for the delivery of therapeutic agents. By definition, nanomaterials are materials or aggregates of
materials in the size range of 1 – 100 nm.17 Li et al. proposed fluorescent theranostic silica
nanoprobes for cancer cell imaging and growth inhibition.18 The nanoprobes were synthesized
using a reverse emulsion method and functionalized to incorporate a cell targeting moiety
(AS1411 aptamer) and 2'-O-methyl-modified miRNA-21 molecular beacon (miR-21-MB) to
particularly recognize miRNA-21 present in breast cancer cells.

The authors reported

monodisperse nanoprobes with an approximate size of 50 nm which demonstrated the ability to
specifically target cancer cells and inhibit cell growth while simultaneously allowing for cancer
cell and intracellular miRNA-21 imaging.
In other work, Deng et al. co-encapsulated MiR-34a—an endogenous tumour suppressor
molecule present in breast cancer cells –and doxorubicin into hyraluronic acid-chitosan
nanoparticles, synthesized using an ionotropic gelation method in water, for breast cancer
therapy.19 The size of nanoparticles containing both MiR-34a and doxorubicin increased as the
amount of hyraluronic acid used in the formulation was increased, and the authors reported
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sustained release of both components in the delivery system for up to 10 days. Furthermore, the
study revealed that the co-delivery of MiR-34a and doxorubicin resulted in the enhancement of
doxorubicin anti-tumour activity, in addition to suppression of cancer cell migration by targeting
the Notch-1 signaling pathway.
Rouhani et al. considered cancer treatment through oxidation therapy—the use of reactive
oxygen species (ROS) as oxidant or anti-oxidant inhibitors to cause apoptosis or necrosis.20 The
authors investigated poly(lactic-co-glycolic acid) (PLGA) nanoparticles loaded with zinc
protoporphyrin (ZnPP) as a heme oxygenase (HO)—an anti-oxidant enzyme known to play a
role in cell growth and proliferation—inhibitor. The average size of the synthesized
nanoparticles was precisely reported to be 100.12±5.345 nm with a smooth, spherical
morphology, and showed potent cytotoxic effects as well as high cellular uptake in PC3 human
prostate cancer cells.

1.3

History of Metallic Compounds for Medical Treatments

Among the various nanoparticles that have been investigated for therapeutic purposes are
magnetic nanoparticles. Although there has been intensive research involving their use for
diagnostic and therapeutic purposes in the last decade, the use of nanoparticles dates hundreds of
years back. Daniel and Astruc described a detailed history of nanoparticles, specifically gold
nanoparticles, as this was one of few metals present in ancient times.21 The authors make
reference to a book written by Francisci Antonii in 1618 on colloidal gold, which is considered
the first book on colloidal gold. The book gives detailed information regarding colloidal gold
sols and their medical uses. He also went further to describe the appearance of a “soluble gold”
in ancient Egypt and China, stating that the “curable powers” of this gold were appreciated until
the Middle Ages. Also, it is noted that in 1676 a book published by Johann Kunckels mentions a
drinkable light pink solution that contains metallic gold capable of curing several diseases.
Although there was little evidence in past civilizations that these metallic compounds in fact
cured diseases, today there is extensive research on the use of nanoparticles for the use in
biomedical applications. For medical applications, a balance between biocompatibility and large
magnetic moments must be achieved, which is why iron-based nanoparticles (such as iron
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oxides) are ideal candidates for medical applications compared to others which are composed of
toxic metals.22

1.3.1

Magnetic Iron Oxide Nanoparticles

Theoretically, magnetic iron oxide nanoparticles can be guided via an external magnetic field to
the site of interest. Among many examples, Carenza et al. evaluated the guidance of magnetic
iron oxide nanoparticles to the brain using an external magnet for neurorepair therapy.13 To date,
these nanovectors have widely been explored for use as contrast agents for imaging modalities
such as computed tomography (CT), positron emission tomography (PET), and magnetic
resonance imaging (MRI) as they present increased sensitivity and short acquisition time,
allowing for the production of high resolution images.23-25 In fact, Ferumoxytol (an FDAapproved magnetite-based product used to treat iron deficient patients) has been clinically tested
for its use as an MRI contrast agent for imaging of the liver.26
Of the many iron oxides available, magnetite (Fe3O4) has received considerable attention for
biomedical applications due to its biocompatibility and biodegradability.27 Many reviews have
been published in literature outlining various synthesis methods, coatings, and applications of
magnetic nanoparticles.27-29 Several methods have been developed to synthesize Fe3O4
nanoparticles. These synthesis methods can be categorized into physical methods, wet chemical
methods, and microbial methods.27 Table 1.1 lists common examples of synthesis techniques for
each category, and the advantages and disadvantages outlined by each.
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Table 1.1: Common synthesis methods for iron oxide nanoparticles27, 29
Category

Physical

Techniques

Electron
beam Easily change/optimize patterns using
lithography
CAD software
Gas-phase
deposition
Chemical
precipitation

Wet
chemical

Microbial

Advantages

Results in 1-dimensional iron oxide
nanostructures

Disadvantages

Poor control of particle size
down to the nm scale

co- Mild reaction conditions, very simple, Difficult to control size and
cheap chemicals
oxidation

Hydrothermal
reaction

Narrow size distribution, tunable
High temperature, and toxic
magnetism, controllable shape and
organic compounds required
crystallinity

Thermal
deposition

Tunable magnetism and size, good High
temperature
crystallinity
pressure required

Microbial
Processes

High yield, good reproducibility, Process takes from several
required low temperature and energy
days up to 3 weeks

and

Also, for biomedical applications, it is desirable to coat the nanoparticle surface in order to
produce biocompatible nanoparticles with chemically reactive groups for additional
functionalization.25 Nanoparticles can be coated with an organic coating using biocompatible
polymers and functionalized through hydrophobic interactions or covalent bonds such as amides.
Inorganic coatings such as silica can also be used to surround the nanoparticle core in a coreshell structure. In fact, these surface coatings play a crucial role in the toxicity and in vivo fate of
the iron oxide nanoparticles as reported by Feng et al.30 Uncoated iron oxide nanoparticles
caused hepatic, renal, and splenic disturbances, specifically in terms of renal toxicity, compared
to coated nanoparticles. However, these disturbances can be reversed, particularly in coated
nanoparticles after excretion, which was attributed to the recovery process observed 48 hours
after administration. Furthermore, uncoated iron oxide nanoparticles tend to gather in biological
fluids resulting in their rapid clearance from the body.31 In comparison, coated iron oxide
nanoparticles, specifically 10 – 100 nm in size, offer a long circulation time in the body. In
addition, the surface chemistry of the particles plays an important role in their uptake by the liver
and spleen. Feng et al. studied the fate of dextran-coated iron oxide nanoparticles and found that
70% of the dextran was found in the urine within 24 hours of administration, and 30% was
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retained over a period of a few days.30 Eventually, these particles are eliminated through the
excretory system.

1.4

Thesis Objectives and Hypothesis

The objective of this thesis project was to develop coated magnetic iron oxide nanoparticles for
the targeted and sustained delivery of curcumin to cancerous cells. In addition, the development
of folate-labeled magnetic nanoparticles for their selective uptake by cancer cells was
investigated. The central hypothesis of this thesis is that coated magnetic nanoparticles will
increase the bioavailability of curcumin to cancer cells, and sustained release will be achieved
depending on the amounts and ratios of molecules used to coat the magnetic core. Furthermore,
folate-labeling will enhance the uptake of nanoparticles by cancer cells. The magnetic properties
of the iron oxide core, along with the selective targeting of the folate ligand is intended to serve
as a dual targeting system to destroy cancer cells, meanwhile rendering healthy tissue unharmed.

1.5

Thesis Outline

We proposed a dual targeting drug delivery system for the sustained delivery of curcumin to
cancer cells. Magnetite (Fe3O4) nanoparticles were synthesized via a simple precipitation method
using only one iron salt, and simultaneously coated with β-cylcodextrin (β-CD) and poly
(propylene glycol) bis (2-aminopropyl ether) (PPG-NH2) during the synthesis process. β-CD is
an FDA approved cyclic molecule composed of seven sugar units, which was used for curcumin
encapsulation. PPG-NH2 is a poly(propylene glycol) with functional amines on both ends of the
molecule. This poly(propylene glycol) derivative was chosen due to its hydrophobic properties
allowing it to be trapped within the β-CD core.32,33 Folic acid will be attached to PPG-NH2
through an amide bond in order to selectively target the folate receptor which is overexpressed
on the surface of cancer cells. With the magnetic properties of iron oxide potentially allowing
magnet-induced guidance to tumour sites, along with the selective targeting of the folate ligand,
this dual targeting system was designed for the destruction of cancer cells without affecting
healthy tissue. Synthesized magnetite nanoparticles containing different ratios of β-CD:PPG-NH2
were characterized using different techniques and tested for their ability to sustain curcumin
release. Chapter 2 gives a detailed description of the chemical properties of curcumin, along with
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its bioactivity for cancer treatment, and previous delivery approaches. The research results of this
thesis are described in detail in Chapter 3.
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Chapter 2
2

Curcumin, a Promising Anti-cancer Therapeutic
2.1

Introduction

For the past few decades there has been rapid growth in the interest of using natural products for
therapeutic applications. Although this idea seems recent, our ancestors frequently used natural
compounds to combat illness. The development of synthetic pharmaceuticals revolutionized
modern medicine over the last century, but the undesirable properties and side effects of these
drugs has inspired a search for natural approaches to disease prevention and treatment with the
hope that naturally occurring compounds may be better tolerated than their synthetic
counterparts. Of particular interest is curcumin, the principal active ingredient in the traditional
dietary spice turmeric, responsible for its colour, taste, and most of its chemical and biological
properties. Curcumin is derived from Curcuma longa, a plant of the ginger family. The other two
curcuminoids present in turmeric in lower concentrations are demethoxycurcumin, and bisdemethoxycurcumin.
While curcumin gained immense attention as a medicinal drug in modern medical applications
only a few decades ago, it has been used for hundreds of years in some areas of the world. In
Asia, specifically India and China, turmeric has been used as a drug for more than two thousand
years.1 Ayurveda, an ancient medicinal system practiced in India, incorporated the use of natural
herbs to treat various illnesses. Amongst the commonly used herbs, turmeric was used most
abundantly due to the medical effects of curcumin. In the traditional Ayurvedic approach,
turmeric was crushed into a paste for the treatment of eye infections, burns, bug bites, and any
skin related diseases. Furthermore, new mothers in India are given a drink containing turmeric
paste, honey, ginger, and milk to drink daily following child birth.1 Turmeric is also used in
different forms to cure cough and respiratory complications, along with dental diseases,
flatulence, and indigestion. Curcumin was also used as a medicine in ancient Polynesian culture.
It has been noted in historical documents that the Polynesian people carried turmeric with them
during long voyages to Hawaii.2 Today, Hawaiians utilize curcumin for various medicinal
purposes. It is known to them as Olena.
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Curcumin was not introduced to Western cultures until the 14th century when European explorers
were introduced to Asian countries. In particular, Marco Polo was introduced to curcumin during
his visit to the Asian continent in 1280 AD.2, 3 It was noted in his writings that the native people
of India and China used a vegetable that contained all the properties of saffron, but this spice was
not quite saffron. In addition, the Portuguese sailor, Vasco de Gama, sailed to India
approximately 500 years ago specifically in search of spices for their medicinal use.4 It was not
until his return to Europe that curcumin was truly introduced into Western cultures. Despite
curcumin’s extensive history, scientists were not able to isolate the curcumin molecule until the
1800s. In 1870, scientists obtained the crystalline form of curcumin, and elucidated its overall
structure in 1910.3 Its chemical structure is responsible for its unique physicochemical and
biological properties.

2.2

Physicochemical Properties

Curcumin, 1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione, is a hydrophobic
polyphenol. It is a golden-yellow solid, with a molecular weight of 368 g/mol and a melting
point of 183 °C. It is often used as a dye owing to its vibrant colour. As shown in Figure 2.1,
curcumin can exist in different tautomeric forms. The aromatic rings are functionalized with
methoxy and hydroxy groups in an ortho position with respect to one another. The aromatic rings
are connected to one another via a seven-carbon spacer that contains two α,β-unsaturated
carbonyl groups. As a result of this structure, a beta-diketone and equilibrating keto-enol
tautomeric forms of curcumin are possible.5
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Figure 2.1: Tautomeric forms of curcumin

2.2.1

Effect of pH

Among the factors that affect the properties of curcumin is pH. Although curcumin has been
shown by X-ray diffraction analysis to exist in the keto-enol form in the solid state,6 there has
been controversy concerning whether curcumin exists in its beta-diketo or keto-enol form at
neutral and slightly acidic pH.5 For example, Jovanovic et al. have proposed that the betadiketone form of curcumin predominates in mildly acidic aqueous solution and in cell
membranes.7 They have also suggested that the central methylene group of the diketone form can
act as a potent hydrogen atom donor in radical reactions, potentially mediating its biological
activity. However, Payton et al. have recently performed detailed NMR studies supporting that
curcumin exists as keto-enol tautomers in a range of hydrophobic and hydrophilic solvents, over
a pH range from 3-9.5 These results are in agreement with density functional theory calculations
by Shen and Li,8 which correlated the calculated absorption wavelength and oscillator strength of
curcumin with the experimental values, supporting the predominance of the keto-enol tautomers.
The keto-enol form was calculated to be more stable than the diketone form by 7.75 kcal/mol.
This was attributed to the planar structure of the enol form, allowing for resonance stabilization
to occur, while that of the ketone form was twisted.
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As shown in Figure 2.2, at pH less than 1, a protonated form of curcumin is observed and the
molecule can adopt a fully conjugated protonated form.9 Figure 2.2 also illustrates the proposed
deprotonated forms of curcumin that can occur as the pH is increased.9 As a consequence of
deprotonation, curcumin exhibits increased aqueous solubility in alkaline solutions while it is
practically insoluble in water at acidic and neutral pH. However, curcumin has been
demonstrated to undergo degradation under alkaline conditions, as demonstrated by Tonnesen et
al. and Wang et al.9, 10

Figure 2.2: Proposed structure of curcumin in (a) acidic, (b) neutral, and (c) basic
environments

2.2.2

Effect of Temperature

Solid curcumin is generally stored at -20°C, though there is no evidence that curcumin is not
stable at somewhat higher temperatures. Wang et al. studied the stability of curcumin at body
temperature.10 In this study, curcumin was incubated under various physiological conditions at
37 °C to measure its stability. Curcumin was incubated in 0.1 M phosphate buffer solution,
culture medium, culture medium with 10% serum, and human blood. Samples were analyzed by
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high performance liquid chromatography (HPLC) after one, four, and eight hours of incubation.
It was noted that the rate of curcumin degradation was dependent on the conditions. When no
serum was present, curcumin underwent degradation more rapidly than in the medium with
serum or in human blood. This difference was accounted for by the stabilization of curcumin by
the serum and it was suggested that care must be taken in the manipulation of curcumin under
serum-free conditions, particularly in the interpretation of the results of biological studies, where
the presence of degradation products such as vanillin should be taken into account.
In another study, Gopinath et al. investigated curcumin incorporated collagen films (CICFs) for
dermal wound healing.11 CICFs were prepared by dissolving a weighed amount of curcumin in
ethanol, and mixing this solution with 50 mL of collagen/acetic acid solution at 4°C for 24 hours.
Micro-shrinkage temperature measurements were carried out on both CICF and pure collagen. It
was found that without curcumin, the shrinkage temperature of collagen was 55°C, which was
increased to 78°C when curcumin was incorporated in the collagen. It was concluded from this
finding that curcumin increases the thermal stability of collagen. This group previously reported
that quercetin also increased the thermal stability of collagen, allowing them to draw the
conclusion that polyphenols are generally capable of enhancing the temperature stability of
collagen and matrices of different types.
Previous studies have demonstrated that natural phenolic compounds suffer from biodegradation,
change of structure, and loss of biological activity when heated. Based on this, Liu et al. set out
to investigate the thermal stability of curcumin.12 Specifically, the relationship between the preincubation temperature of curcumin and its inhibitory effect on amyloid fibrillation of hen eggwhite lysozyme (HEWL) was studied. Unmodified HEWL was used as a control agent, along
with HEWL modified with curcumin pre-incubated at 10, 25, 40, 55, and 70°C for 329 hours.
The result of the Thioflavin T (ThT) fluorescence assay is shown in Figure 3, where a decrease
in fluorescence corresponds to a decrease in amyloids.
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Figure 2.3: ThT assay results, showing that the ability of curcumin to inhibit the amyloid
fibrillation of HEWL (inhibition is detected as a decrease in fluorescence intensity).
Reprinted from reference 12 with permission from Elsevier
As shown in Figure 2.3, the unmodified HEWL exhibited the highest amyloid content, and the
HEWL sample modified with curcumin pre-incubated at 70°C provided similar results. This can
be attributed to the lack of biologically active curcumin following incubation at this temperature.
However, at a pre-incubation temperature of 55°C, it was evident that not all of the curcumin
degraded, as the fluorescence decreased by approximately 50%. Therefore, a clear dependence of
curcumin stability on temperature was observed. This trend was further verified using
transmission electron microscopy (TEM), where the images clearly illustrated the presence of
high amounts of amyloid fibrils in the unmodified HEWL, and that modified with curcumin preincubated at 70°C. However, the samples containing curcumin pre-incubated at lower
temperatures exhibited fewer amyloid fibrils, with the amount decreasing with decreasing preincubation temperature. Similar results were obtained in the cell viability study, leading the
authors to conclude that curcumin is most stable in the temperature range of 10-55°C and
degraded almost completely at 70°C within 24 hours.
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Thus, it can be generally concluded that curcumin is most stable at low temperatures; however,
its stability is still maintained at room temperature and physiological temperature, allowing it to
be used in medical applications. At very high temperatures however, curcumin degrades into
different products, which will be discussed briefly below.

2.2.3

Degradation Products of Curcumin

Under certain conditions curcumin becomes unstable, as previously discussed, and degrades,
yielding other compounds. The three degradation products often found are vanillin, ferulic acid,
and feruloylmethane.13 In the previously described study by Wang et al. it was noted that when
curcumin degraded in different media, the resulting degradation products were characterized by
HPLC-mass spectrometry to be vanillin, ferulic acid, and feruloylmethane.10 However, in this
study there was also an unknown product present in larger amounts. It was hypothesized that this
product was trans-6-(4'-hydroxy-3'-methoxyphenyl)-2, 4-dioxo-5-hexenal.

Figure 2.4: Proposed degradation products of curcumin
A study conducted by Schieffer investigated the degradation products of curcumin obtained after
exposure to light.14 Curcumin is extremely sensitive to light and undergoes degradation in its
presence. The study concluded that curcumin underwent photolytic degradation to produce
several products with the most abundant being p-hydroxybenzaldehyde, vanillic acid, vanillin,
and ferulic acid. The difference in some of the products proposed in this study versus those
obtained by Wang et al. suggests that the thermal and photochemical degradation pathways of
curcumin may be different, though it is generally agreed that the degradation of curcumin is
much more rapid in the presence of light.
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Singh et al. explored the photodegradation of curcumin in the presence of a TiO2catalyst.15 It was
reported that curcumin formed a complex with TiO2, which was evidenced by the presence of a
broad, red-shifted absorption band. Photodegradation was carried out in two solvent media,
water-methanol and water-acetonitrile, and the degradation products were evaluated using gas
chromatography. The results were similar for both media, with the predominant degradation
product being vanillin, along with minimal amounts of CO2, 4-hydroxybenzaldehyde, and
methoxyvanillin.
It is widely proposed that vanillin and ferulic acid are the major degradation products and in fact
contribute to the therapeutic effects of curcumin. In fact, there is a variety of work concerning
the therapeutic effects of vanillin.13, 16-18 Despite the potential therapeutic effects of vanillin, the
recent work of Wang et al. outlined above,10 casts doubt on the proposition that vanillin is in fact
a major degradation product of curcumin. In the case of this study, vanillin and ferulic acid were
only minor degradation products, and there existed a major degradation product with currently
unconfirmed identity.
Gordon and Schneider, and Griesser et al. also performed similar degradation reactions in order
to challenge the belief that vanillin, ferulic acid, and feruloylmethane are the major degradation
products of curcumin.19, 20 The results obtained using HPLC suggested the presence of one major
product, while vanillin, ferulic acid, and feruloylmethane were close to undetectable. Further
analysis revealed a molecular weight of 400 g/mol, indicating insertion of oxygen to curcumin.
Based on 1D and 2D homo- and heteronuclear NMR experiments, the unknown compound was
identified as a bicyclopentadione form of curcumin.19 Figure 2.5 illustrates the proposed
autoxidation mechanism leading to this product. It was proposed that this degradation
mechanism accounts for curcumin’s antioxidant properties, and not the alternative degradation
products.
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Figure 2.5: Proposed mechanism for the autoxidation of curcumin19
Ketron et al. also investigated the oxidative properties of the bicyclopentadione form of
curcumin, exploring its effects on human type II topoisomerases.21 A series of experiments were
performed to evaluate the effect of the bicyclopentadione form of curcumin, stable curcumin,
vanillin, ferulic acid, and feruloylmethane on the human enzymes. The results revealed that the
bicyclopentadione form of curcumin poisons human topoisomerases, in contrast to curcumin and
its three fragmentation products, which did not reveal a significant effect. Thus, while vanillin,
ferulic acid, and feruloylmethane may exhibit therapeutic effects, it still remains to be confirmed
which therapeutic effects of curcumin arise from the parent molecule, and which arise from the
various possible degradation products.

2.3

Effect of Curcumin on Cancer Cells

Although curcumin has been used as a traditional medicine to treat several conditions including
inflammation, respiratory infection, and blood clogging, there is rapidly growing interest in its
effects on cancer. The motivation for the use of curcumin arises not only from its potential
therapeutic effects, but also from the knowledge that it may be better tolerated by patients, in
comparison with most chemotherapeutic drugs that suffer from numerous harmful side effects
such as nausea and vomiting, diarrhea, hair loss,22 and more serious long term conditions such as
liver failure.23 Several studies comparing the incidences of cancer and cancer related deaths in
India and the West revealed lower risk of cancer in India (Table 2.1).24 It is proposed that one of
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the major reasons for the drastic difference in cancer occurrences in these regions is the
increased intake of dietary agents such as curcumin, and other plant derivatives in Asia.
Table 2.1: Comparison of incidences and deaths in India and United States for common
cancers showing cases per 1 million persons24
USA

India

Cancer
Cases

Deaths

Cases

Deaths

Lung

660

580

38

37

Breast

660

160

79

41

Prostate

690

130

20

9

Colon/rectum

530

220

30

18

Bladdar

202

43

15

11

Thyroid

55

5

12

3

Leukemia

100

70

19
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Why does curcumin possess anti-cancer properties? Generally, cancer with its diverse origins has
several molecular markers involved in its onset and progression. Curcumin is capable of
interfering with several biochemical pathways involved in the proliferation and survival of
cancer cells by directly and indirectly binding to different targets. Curcumin has been shown to
interact with various targets including transcription factors, growth factors, DNA, RNA, and
several proteins that are involved in cell signal transduction pathways.25,
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There are several

features of curcumin's chemical structure that make it a favourable and versatile binding partner
for a wide variety of molecular targets (Figure 2.6). For example, curcumin possesses two
hydrophobic phenyl groups connected by a relatively flexible linker. This allows the molecule to
assume different conformations that can maximize π-π and van der Waals interactions with
aromatic and other hydrophobic amino acid residues of proteins. The phenolic hydroxyl and
methoxy groups, as well as the ketone and enol groups present on the ends and in the middle of
the molecule respectively can participate in strong and directed hydrogen-bonding interactions.
The possibility for keto-enol tautomerism introduces additional functionality, with the possibility
to arrange donor and acceptor groups for hydrogen bonding in multiple ways. Furthermore, the
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unsaturated ketone moiety can serve as a Michael acceptor for nucleophilic attack by the
α,β-unsaturated
thiol moieties of cysteine residues or the Se- moieties of selenocysteine. The proposed pathways
by which curcumin exhibits anti--cancer
cancer properties have been described in detail in several recent
reviews25-29 and some of these mechanisms are described below.

Figure 2.6: Structural features of curcumin involved in binding to protein targets
Curcumin’s mechanism of action can occur both intrinsically (mitochondrial) and extrinsically
(mediated via cell surface transmembrane death receptors).30 The intrinsic pathway is generally
g
initiated by activation of tumour suppressor p53 (p53), which is a cell cycle regulator, as well as
through members of the B-cell
cell lymphoma 2 (Bcl
(Bcl-2) family. Up-regulation of p53 activates Bcl-2
homologous antagonist killer (Bak) and Bcl
Bcl-2 associated
ed X protein (Bax), which are propro
apoptotic members of the Bcl-22 family. Bak and Bax promote apoptosis by forming pores in the
mitochondrial membrane releasing cytochrome c into the cytoplasm, thereby activating a caspase
cascade.30 Curcumin is capable of inhibiting Bcl-2 and B-cell
cell lymphoma extra large (Bcl(Bcl
xL)which is another pro-survival
survival protein of the Bcl
Bcl-2 family. Luthra et al.
al showed using
molecular docking studies that curcumin may inhibit Bcl
Bcl-2
2 by directly binding to cavity 2 of the
protein through interactions with multiple amino acids.31 Guo et al. showed that curcumin
significantly inhibited growth of human colorectal carcinoma LoVo cells.32 Nuclear and annexin
V/PI staining confirmed that curcumin induced apoptosis in LoVo cells, in addition to decreasing
d
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the mitochondrial membrane potential and activating caspase-3 and -9 at concentrations of 0 – 30
µM.
Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is a transcription factor involved in the primary
defense pathway against the effects of oxidative stress.33-35 Under normal conditions, Nrf2 is
located in the cytoplasm with its activity suppressed by the chaperon protein Kelch like-ECHassociated protein 1 (Keap1). Under conditions of oxidative stress, which alter the thiol groups
on Keap 1, the Nrf2-Keap1 interaction is disturbed, causing Nrf2 to be transported to the nucleus
where it binds to the anti-oxidative response element (ARE)and activates the transcription of
genes encoding for detoxifying enzymes such as hemeoxygenase-1 (HO-1), which protect
against various forms of stress.36 It has been proposed that Michael addition of curcumin to thiols
on Keap1 may result in a conformational change that disrupts the Nrf2-Keap1 complex,
promoting Nrf2 binding to AREs, but this still requires structural verification.28
Another transcription factor commonly studied as a target for cancer treatment is nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB). This transcription factor is involved in
cell response to free radicals, cytokines, ultraviolet radiation, and viral or bacterial antigens.
Because NF-κB is present in the cytoplasm in an inactive form until stimulated, it is considered a
first responder transcription factor as it does not require synthesis for activation. Upon
stimulation, NF-κB is translocated to the nucleus triggering the expression of certain genes that
suppress apoptosis and promote proliferation and metastasis.
In the work of Youns et al. the effects of curcumin were studied on human pancreatic cell lines
expressing different levels of cyclooxygenase-2 (COX-2), an enzyme that plays an important
role in response to inflammation.37 Curcumin was capable of inhibiting proliferation and
inducing apoptosis through the extrinsic pathway mediated through tumour necrosis factor
(TNF) receptor activation. The TNF pathway triggers caspase-8 and -3 activation, which are proapoptotic, but also induces NF-κB, which regulates the expression of the COX-2 gene. Curcumin
also resulted in down-regulation of COX-2, suggesting the suppression of NF-κB activation.
Using molecular docking studies, curcumin has been shown to bind to TNF-α through various
van der Waals and hydrogen bonding interactions, which may inhibit the binding of TNF-α to its
receptor, thus preventing the activation of NF-κB.38
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In another study, curcumin’s ability to chemosensitize breast cancer cells to 5-fluorouracil was
investigated.39 5-Fluorouracil has been noted to up-regulate the NF-κB pathway inducing the
expression of its regulated genes, leading to chemoresistance. IκB kinase (IKK) is a signalinduced enzyme, which phosphorylates IκBα, an NF-κB inhibitory protein. Upon
phosphorylation, IκBα is detached from NF-κB, leaving NF-κB free to translocate to the nucleus
and induce the expression of different genes. The authors showed that curcumin inhibited the
phosphorylation of IκBα by IKK, preventing the dissociation of IκBα from NF-κB, keeping NFκB dormant. As a result, chemoresistance towards 5-fluorouracil treatment was significantly
decreased.
Activated protein-1 (AP-1), composed of Jun, FOS, and ATF protein dimers,40 is another
transcription factor commonly used as a target for cancer treatment as it is responsible for
differentiation, proliferation, apoptosis, and oncogenic transformations.41 Activation of AP-1 by
stimuli such as growth factors, bacterial/viral infections, cytokines, stress signals, or oncogenic
factors promotes the binding of AP-1 to the TPA responsive element (TRE) causing the
expression of several genes such as cyclin-D1, MMP, VEGF, and uPA, some of which mirror
genes activated by NF-κB and are involved in the angiogenesis and growth of cancer cells.24
Curcumin has been proposed to inhibit this pathway via direct interaction with the AP-1 DNAbinding site.42 Spectroscopic evidence has shown that curcumin can in general bind to DNA
through O2 of thymine in the minor groove, N7 of guanine and adenine in the major groove and
to the backbone phosphate moieties with a binding constant of 4.3 × 104 M-1.43
Curcumin was shown to suppress binding of AP-1 to DNA in human leukemia cells,44 and
transformed keratinocytes.45 Furthermore, curcumin possesses cytotoxic activities towards
human papillomavirus (HPV)-16 and HPV-18 infected cells associated with the development of
cervical cancer, in addition to promotion of cervical cancer cell apoptosis, and inhibition of AP1-DNA binding, thereby preventing HPV gene expression.46 The down regulation of AP-1 by
curcumin has also been reported for prostate cancer.47,48 It was reported that exogenous hydrogen
peroxide induces prostate cancer LNCaP cell proliferation via activation of AP-1 and consequent
stimulation of heparin affin regulatory peptide (HARP) gene.49 This cascade is halted by
curcumin inhibition of the hydrogen peroxide induced HARP expression.
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The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway
is another cascade noted to be involved in the progression of cancer.50 JAK belongs to the nonprotein receptor tyrosine kinase family, and STATs are latent cytoplasmic transcription factors.
The JAK/STAT pathway plays a role in immune response, mediating interactions of cytokines,
hormones, and growth factors and their respective receptors. Upon binding of a ligand to its
receptor, JAK is activated and the increased kinase activity induces phosphorylation of tyrosine
residues on the receptor. Tyrosine phosphorylation creates phosphotyrosine sites on the receptor,
which STATs are capable of binding to. The STATs recruited to these binding sites are
themselves phosphorylated, creating phosphotyrosine sites for other STATs, thereby creating
dimers. STAT dimers accumulate in the nucleus and activate their target genes. Kroon et al.
studied the effect of this pathway on prostate cancer cells, specifically with respect to STAT3
which of the seven known STAT proteins has been reported to be closely associated to a variety
of human cancers.51
Yang et al. investigated the effect of curcumin on the JAK/STAT signaling pathway in small
lung cancer cells.52 The authors reported that curcumin was capable of suppressing cell
proliferation and migration through inhibition of STAT3 phosphorylation, thus suppressing
downstream target genes. To further ensure the role of this cascade on the cancer cells, the
authors showed that activation of STAT3 induced by interleukin-6 (IL-6), a pro-inflammatory
cytokine, lead to increased proliferation and cell survival. These results supported the conclusion
that this pathway can be a potential target for cancer treatment with curcumin. Comparable
results were demonstrated earlier on glioblastomas by Weissenberger et al. in 2010.53
In addition to the above, other molecular signaling pathways reported to be associated with
cancer cell proliferation have also been studied in the context of curcumin. The effect of
curcumin on both the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian
target of rapamycin (mTOR) pathway and the mitogen-activated protein kinases (MAPK)
pathway has been investigated by Ono et al.54 PI3K, a family of enzymes involved in cell
growth, survival, and proliferation, are activated via ligand/receptor interactions where they are
recruited to the inner cell membrane. PI3K activates AKT, which in turn activates mTOR
through direct phosphorylation, promoting cell survival.55 MAPK are activated by a series of
phosphorylation cycles in response to a variety of stimuli. The authors were able to demonstrate
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that curcumin inhibited the phosphorylation of mTOR by AKT, suppressing its downstream
targets and inducing apoptosis. Interestingly, curcumin enhanced MAPK activity. Specifically,
ERK1/2, a subgroup of MAPK, activation by curcumin promoted apoptosis in colorectal
carcinoma cells. As determined by Western blotting, both pathways were associated with G2/M
phase arrest, and poly (ADP-ribose) polymerase (PARP) cleavage, which is characteristic of
cells undergoing apoptosis.
The exportin 1 (CRM1)-dependent nuclear export pathway is a less commonly investigated
cascade. CRM-1 facilitates the transport of large molecules across the nuclear membrane to the
cytoplasm.56 Furthermore, the structure of CRM1 allows the binding of Ran protein bound to
GTP promoting the binding of different cargo proteins to CRM1 in response to a nuclear export
signal (NES). Nui et al. showed that curcumin targets CRM1 through the Michael addition
reaction of the α,β-unsaturated carbonyl of curcumin and the nucleophilic Cys528of CRM1.57
Mass spectrometry revealed that curcumin bound directly to a CRM1-derived peptide containing
the Cys528 moiety, making it capable of arresting this cascade. Furthermore, the authors
investigated the effect of curcumin on cargo proteins, as many cancer-promoting proteins are
trafficked by CRM1. It was found that curcumin treatment caused the up-regulation of tumour
suppressor cargo proteins p73 and p27, and a down-regulation of the pro-survival COX-2 and
Cyclin D1.
In other work, the TNF-related apoptosis-inducing ligand (TRAIL) pathway and its enhancement
by curcumin has been investigated.58 TRAIL is a protein that acts as a ligand, binding to death
receptor (DR)-4 and -5, to activate caspase-8. Caspase-8 cascade activates procaspase-3, -6, and
-7 downstream to induce apoptosis. It was reported that breast cancer cells pre-incubated with
curcumin became sensitized to TRAIL, promoting cell death.58 However, the enhancement of
TRAIL sensitization was cell-type dependent, with the extent of sensitization differing from one
breast cancer cell line to another.
Steroid receptors such as estrogen receptors (ER), progesterone receptors (PR), and androgen
receptors (AR) function as transcription factors, regulating their respective target genes.
Abnormal expression of steroid receptors’ transcription coregulators causes the deviation away
from their normal functions, thereby participating in the onset and progression of cancers.59 For
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this reason, anti-steroid receptor compounds are used clinically to treat cancer due to their
apoptosis-inducing properties.
Curcumin analogues were shown to behave as androgen receptor antagonists in human prostate
cancer as studied by Ohtsu et al.60 Curcumin was identified as a binding ligand for the nuclear
vitamin D receptor (VDR) correlated with human colon cancer, playing a role in cancer
chemoprevention.61 In

particular,

curcumin was capable of competing with 1,25-

dihydroxyvitamin D3 (1,25D) for the direct binding to VDR. Occupation of the VDR binding site
by curcumin caused conformational changes to the receptor, transforming it to its
transcriptionally active form, thereby inducing the expression of tumour suppressor genes.
Moreover, the use of curcumin in breast cancer treatment showed that it can interact with breast
cell lines expressing varying cellular receptor phenotypes involved in breast cancer, thus
inducing anti-proliferative effects.62,63
In addition to anti-proliferative and apoptotic effects, curcumin possess chemosensitizing,64,
radiosensitizing,64,

66

and radioprotective effects.66,

67

65

Furthermore, the effect of curcumin on

newly identified pathways associated with microRNA, stem cells, and autophagy have been
studied.26 MicroRNA are small, noncoding RNAs that negatively regulate the expression of
genes by binding to the 3' region of the untranslated target mRNA, thereby inhibiting translation
or inducing mRNA degradation. Because microRNA possess both oncogenic and tumour
suppressing properties, anti-cancer effects were achieved upon treatment with curcumin, through
the up- and down-regulation of certain microRNA.68-70 Cancer stem cells—undifferentiated
cancer cells that can generate tumours by self-renewal—have been shown to drive and sustain
human cancers, and treatment with curcumin has been demonstrated to interfere with the selfrenewal of cancer stem cells.71-73 Moreover, autophagy is the catabolic or “self-eating”
mechanism involving the sequestration of unnecessary, dysfunctional components or organelles
into autophagosomes and their degradation in lysosomes.74 This process is altered in cancer cells,
promoting cell survival. Curcumin was shown to trigger autophagy in pleural mesothelioma,75
oral cell carcinoma,76 and glioma cells.77, 78 With the many molecular targets of curcumin, indeed
it can serve as a potential therapeutic for the destruction of cancer cells.
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2.4

Clinical Studies

Thus far, more than 20 clinical trials with curcumin for various cancers including colorectal,
pancreatic, breast, prostate, multiple myeloma, lung, head and neck, and cancer lesions have
been completed. The results of these studies have been summarized in recent review
articles,25,26,79 so we describe here only a few recent noteworthy examples.
At a dose of 360 mg, three times per day, curcumin was found to increase body weight, increase
the number of apoptotic cells, and enhance the expression of p53 in colorectal cancer patients
after diagnosis and before surgery.80 However, the health improvement related to increase p53
expression still needs to be studied. Curcumin was also shown to reduce the formation of
aberrant crypt foci (ACF), the precursor of colorectal polyps, in smokers at a dose of 4 g/day,
suggesting a potential cancer chemopreventive role for curcumin.81 A recent study demonstrated
that following doses of 2.35 g/day for 14 days prior to biopsy or colonic resection, curcuminoids
were detectable in colonic tissue, mucosa and urine of most patients, with minimal side effects
observed.82 The efficacy of curcumin in combination with gemcitabine against advanced
pancreatic cancer was also recently evaluated in two different trials.83,84 Kanai et al. found that
curcumin at a 8 g/day in combination with gemcitabine was safe and well-tolerated.84 However,
Epelbaum and coworkers found that some patients experienced abdominal pain at this dose, and
did not obtain a highly promising therapeutic response.83 Curcumin in combination with
docetaxel in patients with advanced and metastatic breast cancer was also recently studied in a
Phase 1 trial.85 It was found that the maximum tolerable dose of curcumin was 8 g/day and in
combination with the standard dose of docetaxel, the recommended dose was 6 g/day for seven
consecutive days every three weeks. The safety, tolerability, and efficacy of curcumin in patients
with asymptomatic, relapsed, or plateau phase multiple myeloma has also evaluated by VadhanRaj et al.86 At doses of 4 to 8 g/day for a year, curcumin was found to down-regulate the
activation of NF-κB and STAT3, and suppress COX-2 expression, but further studies are
required to demonstrate efficacy against multiple myeloma. In patients with familial
ademonmatous polyposis, curcumin was reported to provide improvements in patients with
precancerous lesions at a dose of 12 g/day (0.5% curcumin).87
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Based on a search of www.clinicaltrials.gov, there are currently more than 15 clinical trials
ongoing for the treatment of various cancers with curcumin. Curcumin is approved by the United
States Food and Drug Administration as being generally regarded as safe (GRAS). It is marketed
in various forms as a dietary supplement in many countries. However, there is not yet an
approved drug license for curcumin. This can likely be attributed in part to the multi-targeting
property of curcumin.88 It also results from the extremely poor solubility in aqueous media and
very low bioavailability of curcumin.89,

90

The next section of the review discusses potential

means of increasing the solubility and bioavailability of curcumin in order for the drug to make
the transition from the lab into clinical use.

2.5

Enhancement of Curcumin Solubility and Bioavailability

Curcumin has been reported to be safe at doses up to 12 g/day.91-93 However, because curcumin
undergoes rapid metabolism and clearance when administered, it has very poor bioavailability.94
A study demonstrated that when curcumin was administered orally to rats at a dose of 500
mg/kg, a peak concentration of 1.8 ng/mL was detected in the plasma, while curcumin given
intravenously showed no trace of the drug in plasma within 1 hour of administration.95 In another
study, an intraperitoneal injection of 0.1 g/kg in mice showed a plasma concentration of 2.25
µg/mL after 15 minutes of administration, with concentrations of 177.04, 26.06, 26.9, and 7.51
µg/mL in the intestines, spleen, liver, and kidneys, respectively.96 A human study revealed that a
total oral dose of 3.6 g/day of curcumin resulted in nanomolar amounts of curcumin in plasma
samples on day one at the 1 hour mark, with similar amounts on day 2, 8, and 29.97 How can the
bioavailability of curcumin be enhanced knowing that concentrations of at least 10-5 – 10-4 M are
required for the drug to have any therapeutic impact?95 One approach can involve the coadministration of adjuvants that can block the metabolic processing of curcumin. For example,
the co-administration of curcumin and piperine, a known inhibitor of intestinal and hepatic
glucuronidase, involved in curcumin glucuronidation, was shown to increase the bioavailability
of curcumin by 2000%.98 There has also been ongoing research on drug delivery systems that
may be used to transport curcumin to the desired site, or simply enhance its solubility.
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2.5.1

Preparation of Curcumin Co-crystals

A promising approach to solubility enhancement is the development of co-crystals. Co-crystals
are a class of solid drugs formed using an active pharmaceutical ingredient (API), and a
solubilizing agent.99 The resulting co-crystals generally possess enhanced physicochemical
properties such as solubility and stability, due to increased hydrogen bonds in the system.93
Sanphui and coworkers studied co-crystals synthesized using curcumin as the API with two
different solubilizing agents, resorcinol and pyrogallol (Figure 2.7), by a liquid-assisted grinding
method.93 The melting point of the co-crystals was reported to be between that of pure curcumin
and the solubilizing agent, with curcumin-pyrogallol having a lower melting point than
curcumin-resorcinol. Curcumin-resorcinol co-crystals exhibited a dissolution rate 5-fold that of
curcumin alone, while curcumin-pyrogallol co-crystals had a dissolution rate 12-fold higher than
that of curcumin.

Figure 2.7: Common coformers used with curcumin to produce cocrystals
In another study, curcumin co-crystals were synthesized with five different coformers including
nicotinamide, ferulic acid, hydroquinone, p-hydroxybenzoic acid, and L-tartaric acid (Figure
2.7).90 All five co-crystal solids were noted to be eutectic, having lower melting points than both
constituents alone, and dissolved faster than pure curcumin, with curcumin-nicotinamide having
the fastest dissolution rate. Undoubtedly, curcumin co-crystals can serve as a solution to increase
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the bioavailability of curcumin when administered orally. With the wide variety of coformers
such as therapeutic drugs, salts, or even natural spices, that can be used, curcumin co-crystals can
potentially be synthesized to treat several conditions.

2.5.2

Delivery Systems for Curcumin

Alternative to co-crystals, which simply enhance the dissolution rate of the drug, methods have
been developed to transport curcumin throughout the body to the desired sites for therapeutic
applications. A variety of nano-vehicles including liposomes, exosomes, micelles, nanoparticles,
and dendrimers have been used to encapsulate and deliver curcumin, resulting in enhanced water
solubility, stability and bioactivity (Figure 2.8).

Figure 2.8: Curcumin-loaded drug delivery systems

2.5.2.1

Liposomes

Liposomes can be described as phospholipid bilayers surrounding an aqueous core, and have
been investigated for the delivery of a wide variety of different pharmaceutical agents.100 In fact,
lipid-based drug delivery systems are available in the clinic. One such product is Doxil, which is
a PEGylated liposomal doxorubicin.101 Li et al. have studied the in vitro and in vivo effects of
liposome-encapsulated curcumin on human pancreatic carcinoma cells.102 The liposomes were
prepared from a 10:1 weight ratio of lipid (1,2-dimyristoyl-sn-glycero-3-phosphocholine
(DMPC) and/or 1 ,2-dimyristoyl-sn-glycero-3-phosphor-rac-(1-glycerol) sodium salt (DMPG))
to curcumin. It was demonstrated that liposomal curcumin was capable of down-regulating NFκB machinery, resulting in suppressed growth and increased apoptosis of various human
pancreatic cancer cell lines in vitro. In addition, tumour suppressive and anti-angiogenic effects
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were observed for both BxPC-33 and MiaPaCa2 cell lines in murine models. In a recent study,
Saengkrit et al. investigated thee cellular uptake of curcumin
curcumin-loaded
loaded didecyldimethylammonium
bromide (DDAB)-modified
modified liposomes compared to non
non-modified
modified liposomes on cervical cancer
cells.103 Liposomes were prepared using various ratios of soybean lecithin, non-ionic
non
surfactant,
cholesterol
ol and DDAB by means of the conventional thin film hydration method. The authors
reported that cell uptake was enhanced with DDAB
DDAB-containing
containing liposomes, however the
cytotoxicity of these cationic liposomes was high and more work is required to optimize this.
this
Furthermore, in vitro release studies showed that curcumin was released faster from DDABDDAB
containing liposomes, which the authors hypothesized to be a consequence of reduced interaction
forces between lipid chains due to the cationic charges of DDAB.

2.5.2.2

Exosomes

An alternative to synthetic phospholipid vesicles is the naturally occurring analogue, referred to
as exosomes. Exosomes are small, endocytic membrane vesicles that are excreted by many cells.
They are generally formed by budding from the membrane of multivesicular endosomes found in
different cell types, and thus contain different protein families (Figure 2.9).
9). Exosomes are
usually 30 – 100 nm in diameter and are capable of floating on sucrose gradients making them
easy to separate from other contamin
contaminants.104 Due to their small size and biocompatibility
biocompati
these
vesicles can potentially be used for the delivery of pharmaceuticals.

Figure 2.9: Schematic of the collection and loading of exosomes
Sun et al. studied the anti-inflammatory
inflammatory effects of curcumin when encapsulated in exosomes.105
Curcumin was mixed at 22 °C with exosomes derived from EL
EL-4
4 cells, and the mixture was
purified by sucrose gradient separation. A loading capacity of 2.9 g curcumin per 1 g exosomes
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was reported and the solubility of curcumin was five-fold higher with exosome-entrapment in
comparison to free curcumin. Furthermore, a stability study was conducted and it was found that
in phosphate buffered saline at 37 °C, in the absence of exosomes, 75% of curcumin was
degraded over 2.5 hours, while only 20% degradation was observed for exosome-encapsulated
curcumin. An in vivo study was carried out on mice with a dose of 100 mg/kg of curcumin
administered orally or intraperitoneally. Exosomal curcumin was present in peripheral blood at
concentrations five to ten-fold higher than free curcumin, with no detectable amount of free
curcumin circulating in the blood. The in vivo anti-inflammatory effects of curcumin were also
evaluated, using a lipopolysaccharide-induced septic shock model. A significant survival
advantage and lower cytokine levels were demonstrated for mice treated with exosomal
curcumin in comparison with free curcumin or curcumin-free exosome and saline controls.

2.5.2.3

Micelles

Mohanty et al. proposed a polymeric micelle as a drug delivery system for curcumin
encapsulation to be used for cancer therapy.106 Curcumin-containing micelles were synthesized
using a methoxy poly(ethylene glycol) (mPEG)/poly-ε-caprolactone (PCL) formulation. The
micelles were loaded with curcumin via a dialysis method at room temperature. The micellar
solution was then freeze dried to obtain a dry solid form of curcumin-containing micelles. The
authors reported a curcumin encapsulation efficiency of 60%, with a micelle size of 110 nm. The
loaded micelles showed sustained release of curcumin lasting for one week. Furthermore,
curcumin uptake was investigated on PANC-1 pancreatic cancer cell line using both curcuminloaded micelles, and unmodified curcumin for comparison. Curcumin concentrations of 10, 20,
and 30 µM were studied. The authors observed that cell uptake of curcumin-loaded micelles at a
concentration of 10 µM was ~3-folds higher than that of unmodified curcumin. However, at the
highest curcumin concentration (30 µM), the micellar uptake was only ~2-folds higher than
unmodified curcumin. This led the authors to conclude that cell uptake is more efficient at lower
concentrations, rationalizing that at higher concentrations of curcumin-loaded micelles,
saturation may occur, causing decreased entry of micelles into the cells.
In another study, Podaralla et al. investigated a micellar formulation of curcumin prepared from
mPEG conjugated to zein, a hydrophobic plant protein.107 Curcumin was encapsulated in mPEGzein micelles by dissolving mPEG-zein and curcumin (100:2 wt/wt) in 90% ethanol, followed by
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dialysis to remove the remaining ethanol and free curcumin. The authors reported a micelle size
range of 95 – 125 nm, and release of curcumin over a period of ~24 hours in vitro. The micellar
system resulted in 1000-2000-fold enhancement in curcumin water solubility and a ~6-fold
increase in stability, as evaluated by UV-visible spectroscopy. The uptake of curcumin-loaded
micelles by ovarian cancer cells was 2-3-fold higher than free curcumin, leading the authors to
conclude that this delivery system is highly promising for the delivery of anti-cancer drugs. They
also suggested that the core or shell could potentially be modified by cross-linking in order to
further sustain the release.
Gao et al. studied biodegradable mPEG-poly(lactide) copolymer (mPEG-PLA) micelles for
curcumin delivery in colon cancer therapy.108 The micelles were prepared by a self-assembly
method, and were reported to have a narrow size distribution with an average diameter of 30 nm.
In vitro release studies carried out in PBS containing 0.5% w/w Tween-80 at physiological
temperature showed that free curcumin was rapidly released reaching maximum release (83%)
within 12 hours. However, curcumin-loaded micelles showed more sustained release, reaching
approximately 60% curcumin release in the same time period. The authors also reported
enhanced uptake and apoptosis of colon cancer cells demonstrated by curcumin-loaded micelles
compared to free curcumin alone.

2.5.2.4

Nanoparticles

Nanoparticle vehicles for the encapsulation and transportation of curcumin have also been
developed. For example, in the formulation THERACURMIN, curcumin powder and glycerin
was added to a solution of polysaccharides from ghatti trees, then the mixture was processed by
wet grinding and high-pressure homogenization to produce a stable colloidal dispersion of
nanoparticles with diameters of 190 nm.109 In clinical trials, the area under the blood
concentration-time curve was found to be 27-fold higher for this formulation than for curcumin
powder.109 In addition, in pancreatic or biliary tract cancer patients receiving gemcitabine no
increase in adverse effects was observed for THERACURMIN at a curcumin dose of 200 or
400 mg/day.110
O'Toole et al. have used chitosan-based particles to encapsulate curcumin.111 The authors used a
spray drying method to encapsulate curcumin inside chitosan/Tween 20 particles where the ratio
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of chitosan/Tween 20 was varied. The particle size was noted to be 285 ± 30 nm, with a
curcumin encapsulation efficiency of nearly 100%. In release experiments, a burst release profile
was observed with all of the curcumin released over a period of 2 hours. While suitable for
applications in which a rapid release of curcumin is desired, additional work may be required to
prolong the curcumin release for some applications.
Misra and Sahoo have co-encapsulated curcumin with doxorubicin in poly(D,L-lactide-coglycolide) nanoparticles.112 Doxorubicin is used to treat a variety of cancers, including leukemia;
however, a number of cancer cells, including the chronic myeloid leukemia blasts such as K562
cells are resistant to doxorubicin due to its sequestration into cytoplasmic vesicles and the
induction of multi-drug resistance (MDR). Along with its other anti-cancer properties, as
curcumin has been demonstrated to down-regulate MDR transporters, it was of particular interest
to investigate the potential beneficial effects of incorporating both drugs into a single
nanoparticle. The particles were prepared by a single emulsion, solvent evaporation technique,
which resulted in particles with diameters of ~250 nm. Incorporation of the drugs into the
nanoparticles resulted in ~8-fold higher uptake than for the free drugs in solution. The dual drug
nanoparticle formulation also resulted in increased nuclear retention of doxorubicin. This was
found to correspond to lower levels of expression of resistance genes MDR1 and BCl-2 in K562
cells, attributed to curcumin inhibition. Combined, these properties resulted in increased in vitro
cytotoxicity for the dual drug nanoparticles in comparison to doxorubicin nanoparticles or the
dual drugs in solution.
Curcumin was also encapsulated in another nanoparticle system developed by Mohanty and
Sahoo.113 Curcumin was loaded in glycerol monooleate (GMO)/Pluronic F-127 particles using an
emulsification technique upon the addition of 0.5% w/v polyvinyl alcohol. The nanoparticles
displayed an average diameter of 192 ± 7 nm and had a spherical morphology. HPLC studies
revealed an encapsulation efficiency of 90 ± 3%, and in vitro release experiments demonstrated
an initial burst of 46% of drug released in 24 hours, after which the remaining drug was released
over a period of 10 days. Similar to the cell uptake of curcumin-loaded micelles investigated by
Mohanty et al., the authors found that cell uptake was concentration dependent, with lower
concentrations of curcumin-loaded nanoparticles exhibiting better cell uptake than unmodified
curcumin, in addition to more effective anti-proliferative activity.

35

Sindhu et al. synthesized spherical gold nanoparticles using curcumin alone as a reducing
agent.114 The particles were spherical, with an average size of 58 nm and a zeta potential of -23
mV. The authors reported that the particles were stable at room temperature for up to 6 months,
and that they were non-toxic in vitro. Mesoporous silica nanoparticles (MSN) (type MCM-41)
have also been used to encapsulate curcumin within the pores of the nanoparticles in order to
enhance its solubility.115 The authors demonstrated that the solubility of curcumin encapsulated
in the silica nanoparticles (0.53 µg/mL) was increased by 71% compared to that of curcumin
alone (0.31µg/mL) and curcumin-MSN physical mixture (0.36 µg/mL). The authors noted that in
vitro curcumin release was much more rapid when encapsulated in the MSN, reaching 29% over
72 hours due to the formation of curcumin nano-aggregates in the pores, compared to 8.9% and
9.0% as demonstrated by curcumin and curcumin-MSN physical mixture, respectively. This
resulted in enhanced cytotoxic effects for curcumin-MSN on human breast cancer cells
compared to free curcumin and curcumin-MSN physical mixture.

2.5.2.5

Hydrogels

Though not formally nanomaterials in their simplest form, hydrogels, composed of networks of
polymer chains, are high water-content materials that can possess strength and flexibility similar
to human tissue (Figure 2.10).116 Because there exists a large array of water-soluble polymers
that can be used for the preparation of hydrogels having a wide variety of physical morphologies
(eg. particles, slabs, and films) and properties, hydrogels can potentially be used for many
different biomedical applications including drug delivery. Curcumin-encapsulating hydrogels
containing 0.5, 1, or 2 wt% of a 20 amino acid peptide referred to as MAX8, have been
synthesized via a self-assembly method upon the addition of salt solution buffered to pH 7.4 or
cell culture medium at the same pH, where curcumin-encapsulation and hydrogel formation
occurs concurrently.117 Hydrogels containing curcumin displayed solid-like properties even after
shear thinning, where they were capable of re-healing quickly according to the oscillatory
rheology and shear stiffness study conducted. This suggested their potential as injectable
materials for localized curcumin delivery. The release of curcumin occurred over a period of 14
days and could be modulated to some extent as a function of the MAX8 peptide concentration. In
addition, through in vitro experiments, it was demonstrated that the presence of curcumin in the
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gels inhibited the growth of human medulloblastoma cells on the hydrogel. The bioactivity
hydrogels
of the released curcumin was also confirmed by its ability to inhibit growth of the same cell line.

Figure 2.10: Schematic
hematic of a hydrogel with encapsulated curcumin
An emerging field of hydrogels, called “smart” hydrogels, has gained immense interest. Smart
hydrogels are capable of dramatically changing their properties in response to stimuli such as
temperature, pH, andd chemicals.118 Chen et al. reported a curcumin-loaded
loaded thermosensitive
hydrogel for brain targeting applications through intranasal administration.119 Hydrogels were
synthesized using Pluronic F127 and Poloxamer 188. The curcumin
curcumin-loaded
loaded hydrogels underwent
sol-gel
gel transition in the temperature range 32
32-35 °C, therefore undergoing gelation at
physiological temperatures. In vitro release studies revealed that 80% of curcumin was released
within 6 hours, and in vivo studies showed that curcumin
curcumin-loaded hydrogelss took approximately
one hour to pass from the nasal cavity of rats to their oropharynx. In addition, brain tissue
distribution analyses showed the presence of curcumin in the cerebellum, cerebrum,
hippocampus, olfactory bulb, and plasma after the administ
administration of 250 µg/kg of the nasal
hydrogel. This suggests the application of these curcumin hydrogels for targeting of brain
tumours.

2.5.2.6

Dendrimers and Proteins

In addition to assemblies of phospholipids and polymers into which curcumin can be physically
encapsulated,
psulated, dendrimers have also been widely studied for drug delivery and have often been
used for the preparation of covalent drug conjugates
conjugates.120 Dendrimers are highly branched
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polymers with precise architectures that result from their step-wise synthesis.121 Because these
structures are prepared on a generation
generation-by-generation
generation basis, they can be tailored for use in many
applications. Shi et al. used dendrimers for the enhancement of curcumin’s bioavailability and its
effects in the dissolution of amyloid fib
fibrils.122 The group produced monofunctional derivatives
d
of
curcumin where one of the phenolic groups of curcumin was modified with azide, alkyne, or
carboxylic acid. These monofunctional derivatives of curcumin were then used to produce other
forms of curcumin,
min, among them a polyamidoamine (PAMAM) dendrimer
dendrimer-curcumin
curcumin conjugate
(Figure 2.11). The PAMAM-curcumin
curcumin conjugate was synthesized using a fourth generation
PAMAM dendrimer with a cystamine core and amine surface groups. Curcumin monocarboxylic
acid

was

coupled
pled

to

the

amine

termini

using1,3-dicyclohexyl-carbodiimide,
carbodiimide,

N-

hydroxysuccinimide, and triethanolamine. The biological activity of curcumin was not disrupted
by its chemical modification as reported; In fact the chemical properties of curcumin were
enhanced. The water-soluble
soluble PAMAM
PAMAM-curcumin
curcumin conjugate was able to stain and dissolve
amyloid fibrils in vitro. The enhanced water solubility of curcumin by attachment to dendrimers
suggests promising therapeutic applications
applications.

Figure 2.11: Schematic of the synthesis of a curcumin
curcumin-conjugated
conjugated dendrimer
In another study, with the aim of understanding curcumin's wound healing properties despite its
rapid degradation in aqueous solution, the stabilization of curcumin by four different plasma
proteins, human serum albumin (HSA), fibrinogen, immunoglobulin G (IgG), and transferrin
was investigated.123 It was reported that curcumin degradation was suppressed with a yield of
94.2 ± 13.9% when stabilized with HSA, and 93.6 ± 14.0% with fibrinogen. Transferrin did not

38

suppress curcumin degradation as efficiently (47.8 ± 14.1%), and IgG had no effect on
degradation. The impressive degradation suppression of HSA and fibrinogen were attributed to
the hydrophobic interactions between the proteins and curcumin, where binding of curcumin
takes place in the hydrophobic pocket in the protein. This eliminates interactions with
surrounding water molecules inhibiting curcumin degradation by hydrolysis.

2.6

Conclusions and Future Prospects

With the potential application of the wide range of above vehicles as drug delivery systems come
several challenges. Vesicles often require complex preparation procedures, and are often too
large for drug delivery applications. The large size (> 200 nm) results in clearance by the
reticuloendothelial system (RES) thereby eliminating the drug from the circulatory system.124
Nanoparticles are also often too large to exhibit long circulation times in vivo, frequently having
diameters > 200 nm. In addition, they have some tendency to exhibit an undesirable "burst"
release of the drug. Micelles on the other hand are smaller, and can sometimes exhibit long
circulation times in vivo. However, as they are prepared by self-assembly approaches, their
behaviour in vivo in the presence of membranes and hydrophobic serum proteins, will not always
be the same as their in vitro behaviour in simpler model systems. In addition, the metabolic fate
of these carriers is often difficult to determine, and some may not be biodegradable.
Nevertheless, the work this far has demonstrated the great potential of drug delivery systems to
overcome some of curcumin's problematic properties such as its extremely low aqueous
solubility, stability, and bioavailability.
Although there is still much to be investigated with respect to curcumin and its therapeutic
properties, it has great potential in cancer therapy and prevention. Curcumin is proposed to exert
its anti-cancer effects through a variety of mechanisms including the down-regulation of NF-κB,
the suppression of AP-1 activity, various effects on STAT proteins, as well as other mechanisms.
The controversy regarding curcumin's chemical structure in aqueous solution at neutral pH
appears to be solved, with the dominance of the keto-enol form well supported by NMR
spectroscopy as well as theoretical studies. However, there is still debate as to whether it is
curcumin itself or its degradation products that provide the observed biological activities. This
issue highlights one of the main challenges in working with curcumin - its susceptibility to rapid
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degradation in a wide range of environments and its sensitivity to pH and light. Other major
challenges include curcumin's extremely low aqueous solubility and bioavailability. While
curcumin has been safely administered at high doses in many clinical trials, has achieved the
status of GRAS, and is marketed as a dietary supplement in many countries, it has yet to be
licensed as a drug, likely due to the above-mentioned limitations as well as its multi-target
property.
To address the solubility and bioavailability limitations, a variety of approaches have been
explored to improve its solubility and to deliver it to cancer cells. The formation of co-crystals
with a variety of molecules has resulted in significant enhancements in the curcumin dissolution
rate. Liposomes, micelles, nanoparticles, and other delivery systems have generally led to
enhanced curcumin solubility, stability, cell uptake, and improved biological activities, and are
starting to be evaluated in clinical trials.
Despite the immense progress made on the study and application of curcumin over the last
couple of decades, many questions and challenges still exist. For example, it will be critical to
determine whether the biological properties of curcumin indeed result from the parent compound
or from its degradation products. This is important not only for the fundamental understanding of
this drug but also because the drug delivery systems tend to stabilize curcumin, an advantage that
only persists if this is the bioactive molecule. It will also be important to continue the
development of viable drug delivery systems for curcumin. Here, the critical aspects will involve
the enhancement of curcumin solubility and bioavailability, as well as approaches for selectively
targeting these delivery systems to the disease sites. With this promising progression, the use of
curcumin for the treatment of cancer and other diseases can be envisioned in the near future.
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Chapter 3
3

Synthesis, Characterization, and in vitro Activity of
Curcumin-Loaded
Folic
Acid-Conjugated
Magnetic
Nanoaggregates

3.1 Introduction
For many years cancer has been, and still remains, one of the most difficult diseases to treat.
Despite the sophisticated cancer treatment methods available today compared to when cancer
was first discovered, there remain several drawbacks to the available options. With surgery being
too invasive in many cases, and chemotherapy presenting many adverse side effects such as
vomiting and nausea, hair loss, and liver damage, there has been a drift away from synthetic
pharmaceuticals towards the use of natural medicines. One such medicine is curcumin—a natural
polyphenol derived from turmeric—which has been shown to inhibit cancer cell survival by
inducing apoptosis, and arresting different phases of the cancer cell cycle.1 Due to curcumin’s
poor solubility, there is a strong need for a technology that not only enhances the solubility of
curcumin, but can also transport it to the site of interest in order to avoid its clearance from the
body, and decrease the required dose for treatment.
Of particular interest are magnetic nanoparticles (MNP) due to their small size, biocompatibility,
high stability and surface area, and magnetic properties.2 Because these nanovehicles can be
tailored in terms of size, morphology, and surface chemistry, they have been identified as a
promising technology for virus detection,3 the promotion of human fibroblast growth,4 and most
importantly as contrast agents for diagnosis of cancer using magnetic resonance imaging (MRI).5
Their use as contrast agents for cancer diagnosis has also inspired interest in their use as drug
delivery systems for the potential treatment of cancer.6 Of the available MNP, magnetite (Fe3O4)
has been found in the teeth of chitons, honey bees, homing pigeons and magnetotactic bacteria
and algae, and is generally used as a navigation device.7 Therefore, it is interesting to investigate
this navigational system in humans. Common synthesis methods of iron oxide nanoparticles
include precipitation, thermal decomposition, and hydrothermal/solvothermal synthesis.8
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In order to enhance the stability of curcumin and increase its bioavailability for cancer treatment
it is possible to incorporate it onto magnetite. This can potentially decrease the amount of time it
is left in the circulatory system, thereby avoiding first pass clearance by the reticuloendothelial
system (RES), and it can also decrease the dose required for treatment. Yallapu and coworkers
have explored the potential of curcumin as an anticancer agent,9 and have worked on its
incorporation into magnetite delivery systems. In 2011, Yallapu et al. synthesized βcyclodextrin/pluronic F127 coated magnetite nanoparticles through the co-precipitation of Fe2+
and Fe3+ iron salts in the presence of ammonia.10 This water dispersible system was tested for
hyperthermia, MRI, and drug delivery applications, and showed superior activity for all three
applications compared to pure iron oxide, and β-cyclodextrin-coated iron oxide. In 2012, the
same group synthesized β-cyclodextrin/pluronic F68 coated magnetite nanoparticles using the
same co-precipitation method, and the nanoparticles were then loaded with curcumin.11 The
drug-loaded nanoparticles had an average aggregate size of 123 nm and showed controlled
curcumin release for up to 28 days. Furthermore, the authors reported good cellular uptake and
toxicity in MDA-MB-231 breast cancer cells. Curcumin loaded nanoparticles developed by
Yallapu et al. were also tested in vitro in two human pancreatic cell lines, and in vivo in mouse
models.12 The nanoparticles inhibited the growth of pancreatic cancer cells, and improved
survival of mice by delaying tumour growth. Furthermore, the bioavailability of curcumin in
mice increased 2.5-fold when using drug loaded iron oxide nanoparticles, as compared to free
curcumin.
Several other researchers have worked to incorporate curcumin into magnetite-based
nanovehicles for cancer treatment. For example, Wang et al. developed a core-shell drug
delivery system consisting of a commercial amine modified iron oxide core covalently bound to
a poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) block copolymer shell.13
These nanoparticles were reported to have a diameter of 113 nm as measured by DLS, and
magnetite cores of 15 nm as measured by TEM. In vitro release studies showed 70% curcumin
release over a period of 4 hours, which may need to be optimized for biomedical applications.
Devkota et al. reported the development of a curcumin-loaded alginate/magnetite nanoconjugate
for inductive heating and detection, which can be employed in hyperthermia, biodetection, and
drug delivery applications.14 Nanoparticles were synthesized using the traditional coprecipitation method, and were approximately 120 nm as measured by DLS. The authors also
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reported a decreased saturation magnetization of the curcumin-loaded nanoconjugates (35
emu/g) as compared to uncoated magnetite (60 emu/g); however, nanoconjugates showed a
promising inductive heating capacity and high detection sensitivity, which is beneficial for
hyperthermia and detection applications. Paulino et al. developed hydrogels from different
natural polymeric networks loaded with 50 nm magnetite particles for controlled curcumin
release.15 The authors demonstrated decreased hydrogel swelling in the presence of magnetite
nanoparticles, in addition to magnetic field-induced curcumin release when the magnetite is
stimulated using a magnetic field.
With the promising results obtained by other researchers on the anti-cancer potential of
curcumin-containing magnetite nanoparticles, we propose for the first time to the best of our
knowledge a dual targeting curcumin delivery system for cancer treatment (Figure 3.1).
Magnetite nanoaggregates, synthesized through the precipitation of a single iron salt, are coated
with an amino functionalized poly(propylene glycol) (PPG-NH2), which is used to couple folic
acid at its carboxylic acid. Magnetite nanoaggregates were also simultaneously coated with βcyclodextrin (β-CD) for curcumin encapsulation. Poly(propylene glycols) have been
demonstrated to form complexes with β-CD, where the poply(propylene glycol) is weaved
through the β-CD cavity.16,

17

The magnetic properties of the iron oxide core can allow the

nanovehicle to be guided to the target site, while the folic acid acts as a ligand to selectively
target the folate receptor, which is overexpressed on the cell surface of some cancer cells.18, 19
This dual targeting system will allow for the destruction of cancerous cells meanwhile rendering
the surrounding healthy tissue unharmed.
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Fe 3O4

poly(propylene glycol) bis(2-aminopropyl ether)

β-cyclodextrin

folic acid

curcumin

Figure 3.1: Schematic of a folic acid-conjugated curcumin-loaded magnetic nanoparticle

3.2

Materials

The iron precursor ferrous sulphate heptahydrate (FeSO4·7H2O) was purchased from VWR
International. β-cyclodextrin (β-CD) (MW: 1135 g/mol) was purchased from Sigma-Aldrich
along with poly(propylene glycol) bis(2-aminopropyl ether) (PPG-NH2) (MW: 2000 g/mol),
curcumin (MW: 368 g/mol), and N, N-diisopropylethylamine (DIPEA) (MW: 129.25 g/mol).
Folic acid (FA) (441 g/mol) and fluorescein isothiocyanate (FITC) (389 g/mol) were purchased
from Alfa Aesar. 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) (MW: 155.24 g/mol)
was purchased from Advanced ChemTech, and ammonium hydroxide (NH4OH) and
dimethylsulfoxide (DMSO) were obtained from VWR.
For the cell studies, MDA-MB-231 cells were obtained from American Type Culture Collection
(Manassas, VA) and maintained in DMEM/F12 + 10% fetal bovine serum (FBS). MDA-MB-468
cells were obtained from Dr. Janet Price (MD Anderson Cancer Center, Houston, TX) and
maintained in αMEM + 10% FBS. All growth media and supplements were obtained from
Invitrogen (Carlsbad, CA). FBS was obtained from Sigma-Aldrich (St. Louis, MO). All plastics
were from Nunc™ (Thermo Fisher Scientific, Ottawa, ON). All cells were incubated at 37°C
under a 5% CO2 atmosphere.
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3.3

Synthesis Procedures

Figure 3.2 shows the overall synthesis process, and the contents of each sample synthesized is
summarized in Table 3.1.

+ NH4OH

CH3

FeSO4·
H2N

CH3
O
n

-cyclodextrin ( -CD)
H2O
80 C, 90 mins.

NH2

S1 - S4

poly(propylene glycol) bis(2-aminopropyl ether)
(PPG-NH2)

HO

OH

H3CO
folic acid

S1 - S4

acetone/H2O
room temperature, 24 hr

S1FA - S4FA
(from S1 - S4)

EDC/DIPEA

HO

OH

H3CO

OCH3
O

OCH3
O OH
curcumin

OH

curcumin

S1c - S4c
(from S1 - S4)

Figure 3.2: Chemical scheme of synthesis process

acetone/H2O
room temperature, 24 hr

S1FAc - S4FAc
(from S1FA - S4FA)
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Table 3.1: Polymer compositions, and folic acid and curcumin content of synthesized
samples
Sample
S1
S2
S3
S4
S1c
S2c
S3c
S4c
S1FA
S2FA
S3FA
S4FA
S1FAc
S2FAc
S3FAc
S4FAc

3.3.1

mmol PPG-NH2 : mmol β-CD
Folic Acid Curcumin
(FeSO4·7H2O is constant at 5 mmol)
0.25 : 1.0
0.50 : 1.0
1.0 : 0.50
1.0 : 1.0
0.25 : 1.0
+
0.50 : 1.0
+
1.0 : 0.50
+
1.0 : 1.0
+
0.25 : 1.0
+
0.50 : 1.0
+
1.0 : 0.50
+
1.0 : 1.0
+
0.25 : 1.0
+
+
0.50 : 1.0
+
+
1.0 : 0.50
+
+
1.0 : 1.0
+
+

Preparation of PPG-NH2/β-CD Coated Nanoaggregates Sample
S4 and Representative Procedure for the Preparation of Samples
S1 – S3

Magnetic nanoaggregates were synthesized based on a modified method reported by Ragab et
al.20 1.40g (5 mmol) of the iron precursor FeSO4·7H2O were dissolved in 50 mL distilled water,
and 2 mL (1 mmol) of PPG-NH2 was added to the dissolved precursor under stirring (400 rpm)
and left until a colour change was noticed (green to orange/yellow). 1.20 g (1 mmol) of β-CD
dissolved in 20 mL of ammonium hydroxide (NH4OH) was gradually added to this mixture, at
which point stirring was immediately increased to 1200 rpm and the temperature was increased
to 80°C. The mixture was covered and left for 90 minutes under stirring. The prepared sample
(S4) was separated from the supernatant using a magnet and the supernatant was removed using
a pipette. The particles were then redispersed in distilled water. The sample was then recollected
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using the magnet and the distilled water was removed before the sample was redispersed in
ethanol. The sample was washed 3 times in ethanol using this procedure, and then dried at 60°C.
Samples S1 – S3 were prepared in the same manner, but the absolute amounts of PPG-NH2 and
β-CD were reduced according to Table 3.1.

3.3.2

Functionalization of PPG-NH2/β-CD-Coated
Samples with Folic Acid

Nanoaggregates

Samples S1 – S4 were functionalized with folic acid using the following method. 20 mg (46
µmol) of folic acid were dissolved in 10 mL of DMSO containing 20 μL (92 µmol) of DIPEA in
a nitrogen atmosphere. This solution was added to 20 mg of dry polymer-coated nanoaggregates
(S1 – S4), after which 10 mL of DMSO containing 7 mg (46µmol) of EDC was added under
nitrogen. The samples were left shaking in a water bath for 2 days, initially at room temperature
for the first 3 hours, after which the temperature was increased to 35°C. After removal of the
samples from the water bath, the aggregates were left on a magnetic plate to settle completely
before the folic acid content in the supernatant was analyzed using UV-visible spectroscopy to
quantify the amount of folic acid attached. The folic acid functionalized nanoaggregates (S1FA –
S4FA) were then separated using a magnet, the supernatant was removed, and the samples were
redispersed in ethanol for washing. The samples were recollected with a magnet, the ethanol
supernatant removed, and the samples were dispersed again in ethanol. This washing procedure
was carried out 3 times, and the samples were dried at 50°C.

3.3.3

β-CD/curcumin Complex Synthesis and Curcumin Loading of
Nanoaggregates

β-CD/curcumin complex was synthesized by adding a solution containing 36 mg ( ) of curcumin
in 1.5 mL of acetone to a solution of 120 mg ( ) of β-CD in 24 mL distilled water under stirring
(400 rpm). The mixture was left for 24 hours before the supernatant was collected by
centrifugation and freeze dried for 24 hours to obtain a dry β-CD/curcumin complex solid. The
synthesized complex, along with β-CD, and curcumin were analyzed using proton nuclear
magnetic resonance (1H NMR).
Nanoaggregate samples were loaded with curcumin via a modified method reported by Yallapu
et al. to produce curcumin loaded samples.11 10 mg of nanoaggregates were dispersed in 2.8 mL
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of distilled water under stirring at 400 rpm. Curcumin (1.0, 1.5, 2.0, 3.0, or 5.0 mg) was
dissolved in 200 µL of acetone and added dropwise to the nanoaggregate suspension. The
mixture was stirred for 24 hours at room temperature. The resulting curcumin-loaded
nanoaggregates (S1c – S4c and S1FAc – S4FAc) were thoroughly washed with distilled water by
magnetically collecting the samples, removing the supernatant, and re-adding distilled water. The
washing process was carried out 6 times. Samples were then freeze dried to obtain dry
nanoaggregates. To determine the loading efficiency, 5.0 mg of curcumin loaded nanoaggregates
were suspended in 10 mL of ethanol. The samples were left shaking in a water bath at 25 °C for
24 hours, after which samples were removed from the water bath and placed on a magnetic plate
to allow the nanoaggregates to settle. The supernatant was collected using a pipette and the
curcumin content was measured using UV-visible spectroscopy at 427 nm.

3.3.4

Preparation of FITC-labeled Particles

1.0 mg FITC were dissolved in 3 mL acetone/water (0.3/2.7 v/v) mixture and added to a
dispersion of magnetic nanoaggregates (10 mg) in 10 mL of PBS. The reaction was left stirring
at 1000 rpm in the dark for 24 hours at room temperature. The resulting FITC-labeled samples
were washed with PBS and stored at 4°C. Similar fluorescence of FITC-labeled samples was
obtained, as measured by a Photon Technology International (PTI) fluorometer. 1 mg of FITClabeled nanoagreggates was suspended in 1 mL of PBS and measured at an emission range of
450 – 650 nm, an excitation wavelength of 494 nm, a length of 200 nm, step size of 0.5 nm, and
integration of 0.1 seconds.

3.4
3.4.1

Characterization of Synthesized Nanoaggregates
Particle Morphology

The general morphology of the synthesized nanoaggregates was examined using a Philips CM 10
transmission electron microscope operating at 80 kV. Samples were prepared on Formvar
carbon-coated-100-mesh copper grids. One drop of a 0.50 mg/mL nanoaggregate suspension was
used to cover the grid surface. Excess water was removed using fine filter paper, and the grid
was left for approximately 30 minutes to dry in air prior to examination.
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3.4.2

Particle Size Analysis

The mean diameter of the individual particles and the polydispersity indices were determined
using a Malvern Instruments Ltd. Zetasizer 3000 HSA particle sizer. The size analysis was
performed at a scattering angle of 90° and room temperature. Nanoparticle suspensions (1.0
mg/mL) were prepared and diluted by a factor of 45 to obtain homogeneous suspensions of
nanoparticles. Three runs were carried out per sample in order to obtain a standard deviation.
The aggregate size was determined using a Malvern Instruments Ltd. Zetasizer Nano ZS.
Samples were prepared at concentrations of 0.50 mg/mL and analyzed at a measurement angle of
173° at room temperature. Samples were run three times each in order to obtain a standard
deviation value.

3.4.3

X-ray Diffraction (XRD) Analysis

The crystal structures of the samples were analyzed using a Rigaku-Miniflex X-ray
diffractometer (The Woodlands, TX). The samples were exposed to radiation (CuKα (30 kV, 15
mA)) at a wavelength of 1.54 Å, and scanned over a 2θ range of 5 - 90° with a step size of 0.05°.

3.4.4

Fourier Transform Infrared (FTIR) Spectroscopy

A Bruker-Tensor 27 (Germany) spectrophotometer was used to obtain the FTIR spectra of the
samples in the solid state. Samples were mixed with potassium bromide in a 1.0:10 w/w ratio and
pressed into a disc prior to examination. Samples were scanned between 4000 – 600 cm-1 at a
scanning speed of 4 cm-1.

3.4.5

Vibrating Sample Magnetometer (VSM) Measurements

A model 74035 VSM was used to explore the magnetic properties of the samples.
Approximately 15 mg of sample were added in the sample holder, after which the samples were
exposed to a magnetic field at a field range of ±10000 G.
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3.5
3.5.1

In vitro Studies Experimental Procedures
Curcumin Release

In vitro curcumin release was carried out at 37°C in a water bath under constant shaking. Briefly,
1.0 mg of curcumin-loaded nanoaggregates was dispersed in 10 mL of PBS containing 0.10%
Tween 80. At predetermined intervals, the supernatant was collected and fresh buffer/Tween
solution was replaced in the sample vials. The collected supernatant was measured using UVvisible spectroscopy at 427 nm.

3.5.2

In vitro Cytotoxicity Assays

MDA-MB-231 and MDA-MB-468 cells were plated in 100 µL of culture medium at a density of
2.5 x 104 cells/well in 96-well plates. After 24 hours, various treatments (sample S2, sample S2c,
sample S2FA, sample S2FAc [up to 2000 μg/mL of particles], or free curcumin [up to 260
μg/mL] (Sigma-Aldrich, St. Louis MO)) were added to the cells and incubated for 48 hours. Cell
viability was determined using the Alamar Blue Assay (Life Technologies, Inc., Burlington,
ON).

3.5.3

Flow Cytometry Analysis

For assessment of folate receptor expression, human breast cancer cells were harvested and
stained with a mouse anti-human folate receptor antibody (LK26, AbcamInc, Cambridge MA)
for 30 min at 4 °C. After removal of excess antibody by PBS washing, cells were incubated with
AlexaFluor488-conjugated goat anti-mouse IgG (Life Technologies) for another 30 min at 4 °C,
washed with PBS, and analyzed by flow cytometry using a Beckman Coulter EPICS XL-MCL
flow cytometer.
For assessment of nanoparticle uptake, human breast cancer cells were seeded into 60mm culture
dishes and grown until 80% confluent. FITC-labeled sample S2or S2FA (2000 µg/mL) were
added to the cells. After 4 hours incubation at 37 °C, particles that were not internalized were
washed away using PBS and cells were harvested. Extracellular FITC was quenched by
incubating with 200 µg/mL Trypan Blue (Sigma-Aldrich) for 10 min at room temperature. Cells
were washed using PBS and analyzed by flow cytometry.
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3.6
3.6.1

Results and Discussion
Nanoaggregate Synthesis

Magnetic nanoaggregate samples were synthesized using a precipitation method involving one
iron salt, as compared to the traditional co-precipitation method where Fe2+ and Fe3+ salts must
be used with the iron cations having a precise 1:2 molar ratio. The traditional method involves
the need for strict oxidation control in order to avoid the formation of γ-Fe2O3 instead of Fe3O4,
which requires a complicated experimental setup in order to run the reaction under a nitrogen
atmosphere. Therefore, the method employed here is advantageous due to its simplicity and is
carried out based on the following reactions:
Fe2+ + 2OH-Fe(OH)2
4Fe(OH)2 + O2 4FeOOH + 2H2O
FeOOH + 2Fe(OH)2 + 5OH-  Fe3O4 + 5H2O + O2
Nanoaggregates were synthesized by the addition of β-CD to a mixture of ferrous sulphate and
PPG-NH2 under alkaline conditions (Figure 3.2), as a high pH promotes small particle
formation,21 which is desirable for biomedical applications. Another factor that was employed to
control the particle size was the addition of PPG-NH2, as this polymer can act as a stabilizer by
adsorbing on the crystal structure surface.21 The resulting reduction in surface tension causes a
reduction in the Gibbs free energy and consequently an increase in nucleation rate, resulting in
smaller particle size. In solution, the metal component of the precursor forms seeds which allow
the growth of metal ions or metal-stabilizer complexes (monomers) on the surface, forming
crystals.21, 22 Therefore, with fast nucleation more seeds are present to consume monomers on
their surfaces, yielding smaller particles (Figure 3.3). However, under conditions of slow
nucleation, few seeds are produced, which consume a larger amount of the produced monomers
on their surface.
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Figure 3.3: Nucleation and growth schematic
Figure 3.2 briefly outlines the synthesis process. PPG-NH2 and β-CD were added in different
amounts as shown in Table 3 to obtain samples with varying PPG-NH2/β-CD ratios (S1 – S4),
which were then used to produce folic acid functionalized samples (S1FA – S4FA). Samples
with and without folic acid were then loaded with curcumin to obtain both folate positive, and
folate negative drug loaded samples for future experiments (Table 3.1).

3.6.2

Nanoaggregate Characterization

The size of drug delivery vehicles is one of the most important parameters to be considered for
biomedical applications. Particle size analysis was carried out to determine the size of both the
individual particles, as well as the aggregates formed (Table 3.2). Generally, there was a slight
decrease in the average individual particle size when the amount of PPG-NH2in the system was
higher than the amount of β-CD, as demonstrated by the results for samples S1, S2, S3, and S4.
This may be attributed to the interference of the polymer with the growth of the crystals upon
adsorption on the crystal surfaces.21, 23 The desired size range of individual nanoparticles was 10
– 20 nm. The sizes of the individual particles were measured by DLS following sonication for 5
seconds followed by dispersion using a vortex and then immediate dilutions until a clear light
yellow, homogeneous solution was obtained. Sample diameters were in the expected size range.
Aggregates were also measured by DLS following dispersion using a vortex and allowing the
sample to reach an equilibrium aggregation state. Aggregates grow to decrease surface energy,
and aggregation is generally dependant on particle-particle interactions.21 In general, samples
formed smaller aggregates with increasing ratio of PPG-NH2:β-CD suggesting that PPG-NH2
helps stabilize the particles, thereby decreasing particle-particle interactions. However, S2 did
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not follow this trend completely. The specific ratio of PPG-NH2 to β-CD present in S2 may be
ideal for decreasing particle-particle interactions which may explain why the aggregate size is
less than the other samples.
Table 3.2: Individual particle sizeand aggregate size of synthesized samples
Sample

S1

S2

S3

S4

Aggregate Diameter (nm)

1000 ± 75

223 ± 10

443 ± 9

355 ± 5

Polydispersity index

0.35 ± 0.09 0.30 ± 0.06 0.31 ± 0.06 0.43 ± 0.02

Individual Particle Diameter (nm)
Polydispersity index

13 ± 5.6

10 ± 6

9.1 ± 3.4

11 ± 6.5

0.20 ± 0.1

0.24 ± 0.07 0.28 ± 0.07 0.27 ± 0.1

Samples were chosen for transmission electron microscopy (TEM) analysis in order to study the
morphologies of the nanoaggregates. Uncoated nanoaggregates and sample S2 were chosen as
representative samples for comparison (Figure 3.4). Images confirmed that the nanoparticles
have spherical, uniform morphologies that form aggregates. However, this aggregation is
reversible, meaning that certain techniques can be employed to obtain individual nanoparticles.
One such technique is the use of surfactants or surface coatings at specific pH values to create a
surface charge on the iron oxide nanoparticles.21,

24

Such surface charges can create repulsive

forces, promoting deaggregation. This is demonstrated on iron oxide nanoparticles upon polymer
coating, when compared to uncoated samples (Figure 3.4).
In other work, Stuyven et al. showed that deaggregation of Ludox® silica sol samples in a KNO3
solution depended on the presence of a magnetic field (0.31 T), and the type of flow.25 The
authors showed that in the presence of a magnetic field, under turbulent flow conditions, particle
size decreased (deaggregation) and a narrow size distribution was established. However, under
laminar flow conditions (such as that seen in blood flow) aggregation was the dominant
condition even with the presence of a magnetic field. This was attributed to the movement of
charged particles to the channel wall where velocity is low. Based on this study, it would be
interesting to employ a similar experiment on the current iron oxide samples—as they show
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better magnetic properties than silica—by increasing the magnetic field gradually under laminar
flow conditions and recording the aggregation behaviour.

(a)

(b)
B

Figure 3.4: TEM images of A) uncoated nanoaggregates, and B) sample S2
For biomedical applications, it is not only important to optimize the surface properties of the
delivery system, but also the amount of drug loaded. In order to maximize the amount of
curcumin in the system, it is beneficial to have more β-CD than PPG-NH2 in the nanoparticle
system. For this reason, samples S1 and S2, along with their folic acid conjugated counterparts
(S1FA and S2FA), were chosen for future experiments. Also, samples S2 and S2FA were chosen
as representative samples for the remainder of the characterization studies used.
X-ray diffractometry (XRD) was used to analyze the crystallinity of the iron oxide samples.
XRD was carried out on uncoated nanoaggregates, and samples S2 and S2FA to ensure that the
samples produced are in fact magnetite, and that their crystal structure remained unchanged after
polymer coating, and folic acid functionalization. The five characteristic peaks noted for each
sample are at 2θ angles of approximately 30°, 35°, 43°, 57°, and 62° (Figure 3.5a) with the same
relative intensities, indicating a retained crystal structure of nanoparticles as peak shifting was
not observed. Furthermore, the peak positions along with the relative peak intensities of each
sample were compared with the standard XRD pattern for magnetite corresponding to ICCD card
number 00-019-0629 obtained using the PDF-4+ software (Figure 3.5b).The full standard
magnetite XRD pattern corresponding to ICCD card number 00-019-0629 is presented in
Appendix 1. It was verified that the synthesized nanoparticles are magnetite based on the peak
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position and intensities of the standard XRD pattern, which matched those obtained by the
synthesized samples. Magnetite has the chemical formula Fe3O4 where the iron component
consists of both FeII and FeIII. Magnetite has an inverse spinel structure where the FeII ions are all
in octahedral sites and the FeIII ions occupy both tetrahedral and octahedral sites.26 In addition,
the oxygen atoms have a face centred cubic close packed alignment along [111].

(a)

(b)
S2FA

S2
uncoated
nanoaggregates

20

40

60

80

2Theta

Figure 3.5: a) XRD spectra of synthesized samples, and b) standard XRD pattern of
magnetite (See Appendix 1).
The magnetic properties of uncoated nanoaggregates, and sample S2 were studied to determine
how the magnetic properties of Fe3O4 are affected by the presence of surface coatings (Figure
3.6a). Magnetite is ferrimagnetic at room temperature due to the presence of at least two
sublattices composed of the two different cationic sites in the structure (tetrahedral site of Fe3+
and octahedral site of both Fe3+ and Fe2+).27 However, magnetite shows super-paramagnetic
behaviour as the size of the particles decreases (~≤ 20 nm),27,

28

and as a result of the easy

magnetization along the crystallographic axis [111] present in the structure.26 This is evident by
the low coercivity of each sample (Figure 3.6b) which is characteristic of super-paramagnetic
materials. Surface modification of the nanoparticles decreased the saturation magnetization (Ms)
and the corresponding magnetic properties, but not significantly, which is beneficial for the
desired application.
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Figure 3.6: a) Magnetization curves of uncoated nanoaggregates and sample S2 and b)
their corresponding magnetic properties.
Because nuclear magnetic resonance (NMR) could not be used to verify the presence of certain
functional groups due to the magnetic properties of the aggregates, FTIR spectra of uncoated
nanoaggregates, β-CD, PPG-NH2, and samples S2 and S2FA were obtained in order to ensure
the successful synthesis of nanoparticles, and coupling of folic acid on the amino terminus of the
PPG-NH2. FTIR spectra are presented in Figure 3.7, and the major peaks at wavenumbers higher
than 1500 cm-1 are indicated. A peak is observed on uncoated magnetite nanoaggregates at
approximately 3450 cm-1 due to O-H stretching vibrations (Figure 3.7a), in addition to the peak
present at 1630 cm-1 corresponding to H-O-H stretching vibrations of residual water in the
sample.29 As shown in Figure 3.7b for β-CD, the broad stretch between 3000 cm-1 and 3500 cm-1
corresponds to the presence of O-H groups of β-CD and the peak at 1630 cm-1 is characteristic of
H-O-H stretching vibrations.30 β-CD also has a characteristic peak at 2900 cm-1 caused by C-H
stretching vibrations of CH2. The infrared spectrum of PPG-NH2 (Figure 3.7c) contains a strong
peak between 2800 cm-1 and 3000 cm-1 corresponding to C-H stretching. For S2, as shown in
Figure 3.7e, a combination of these peaks corresponding to the magnetite, β-CD, and PPG-NH2
were observed. Sample S2FA (Figure 3.7f) also includes these characteristic peaks, however the
C-H stretch intensity between 2800 cm-1 and 3000 cm-1 is decreased and the peak in the region of
3000 – 3500 cm-1is broadened, suggesting the possible presence of an N-H stretch from the
amide bond that is formed upon conjugation. Two peaks were also observed in the region of
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1600 – 1650 cm-1, suggesting the presence of a C=O stretch from the amide bond, adjacent to the
H-O-H stretch.

overlapping H-O-H
& C=O stretches (f)

C-H stretch
O-H stretch

H-O-H
stretch

% Transmittance

C-H stretch
O-H stretch

(e)

(d)

C-H stretch

(c)
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H-O-H
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O-H stretch

H-O-H
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(a)
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Figure 3.7: FTIR spectra of (a) uncoated nanoaggregates, (b) β-CD, (c) PPG-NH2, (d) folic
acid, (e) sample S2, and (f) sample S2FA
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The amount of folic acid attached was quantified to further ensure its presence on nanostructures.
The amount of folic acid to nanoaggregates was selected through the modification of a method
reported by Sun et al.31 The presence of folic acid conjugated to the amino terminals was
measured to be 27±9% and 23±6% for samples S1FA and S2FA, respectively. This was
calculated based on the folic acid content remaining in the supernatant (as measured by UVvisible spectroscopy) following the coupling process using the following equation:

%= ݊݅ݐܽ݃ݑ݆݊ܥ

ௐ ିௐೞ
ௐ

× 100%

(1)

where, wi is the weight of folic acid used in the coupling reaction, and ws is the weight of folic
acid remaining in the supernatant. Despite S2 having more PPG-NH2 in the system, the amount
of FA conjugated to S1 and S2 were statistically equivalent to one another.

3.6.3

Curcumin Loading and in vitro Release

To ensure curcumin’s presence within the β-CD cavities, a β-CD/curcumin complex was
synthesized and studied using nuclear magnetic resonance (NMR). The characteristic chemical
shifts of β-CD and curcumin were first determined (Appendix 2) and then used for comparison
with the NMR spectrum of the synthesized complex. An NMR spectrum of the complex was
obtained in deuterated water (Appendix 3) and only the chemical shifts of β-CD were observed.
However, when an NMR spectrum of the complex was obtained in deuterated acetone (Appendix
4) chemical shifts of both β-CD and curcumin are observed. Because curcumin is soluble in
acetone, it acted to extract the curcumin from the β-CD cavities.
In order to optimize the loading of curcumin, curcumin was added in varying amounts to samples
S1 and S2 to obtain samples S1c and S2c, and the corresponding encapsulation efficiencies were
obtained (Figure 3.8). The resulting trend revealed that the encapsulation efficiencies increased
up to 0.3 mg/mg of MNP, then decreased at the highest curcumin amount of 0.5 mg/mg of MNP.
Therefore, based on the results shown in Figure 3.8, the optimal amount of curcumin was chosen
to be 0.3 mg/mg of MNP. At this loading ratio, encapsulation efficiencies of 73±4% and 86±5%
were obtained for S1c and S2c, respectively, corresponding to drug contents of 23±1 % w/w and
26±2 % w/w. Because S1 forms large aggregates as stated previously, the high aggregation may
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hinder the ability of curcumin to enter the β-CD
CD cavity. This can explain may sample S2c has
higher encapsulation efficiency compared to S1c.W
S1c.When
hen samples containing folic acid (S1FA and
S2FA) were loaded at 0.3 mg/mg of MNP to obtain
in samples S1FAc and S2FAc, considerably
lower encapsulation efficiencies of 41±4% and 31±
31±2% were obtained, corresponding to drug
contents of 12±1% and 9.0±0.40%, respectively. This significant decrease in drug loading is
attributed to the presence of foli
folicc acid, preventing the diffusion of curcumin into the β-CD
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Figure 3.8: Encapsulation efficiency trends for samples S1c and S2c
The in vitro curcumin release profiles of samples S1c, S2c, S1FAc, and S2FAc were obtained to
study the type of drug release demon
demonstrated by each system (Figure 3.9).
). Generally, the four
samples demonstrated a sustained release profile, but over varying time periods.
periods Comparing S1c
and S2c, sample S2c shows more sustained release of curcumin, which might be attributed to the
presence of higher amounts of PPG
PPG-NH2. The presence of higher amounts of PPG-NH
PPG
2 likely
increases the hydrophobic interactions with curcumin which must be disrupted in order for the
drug to diffuse. Sampless S1c and S1FAc show similar release behaviours, however samples S2c
and S2FAc show quite different trends. T
The
he time of sustained release decreased from 11 days as
demonstrated by sample S2c, to 3 days corresponding to S2FAc.. This is likely due to the
presence
ence of the bulky folic acid molecules attached to the PPG
PPG-NH2 terminals. Because curcumin
is loaded after folic acid conjugation, the presence of PPG-NH2 in addition to folic acid on the
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surface may make it difficult for curcumin to securely enter the β-CD cavity and is left loosely
encapsulated or entrapped on the surface. Based on these results, it is possible to optimize the
release and sustain it for a longer period of time through the manipulation of the amount of PPGNH2, and consequently the amount of folic acid that will be on the surface.

100
Cumulative % Curcumin Released

Cumulative % Curcumin Released

100

80

60

40

20

(a)
0

80

60

40

20

(b)
0

0

0.5

1

1.5

2

2.5

3

3.5

0

1

2

Time (days)

4

5

100
Cumulative % Curcumin Released

100
Cumulative % Curcumin Released

3
Time (days)

80
60
40
20

(c)
0

80
60
40
20

(d)
0

0

2

4

6
Time (days)

8

10

12

0

0.5

1

1.5

2

2.5

3

3.5

Time (days)

Figure 3.9: In vitro curcumin release profiles for (a) S1c, (b) S1FAc, (c) S2c, and (d) S2FAc
To further analyze the release behaviour of the drug delivery system, it may be beneficial to
describe each profile using a mathematical model. The Ritger-Peppas model can be used to
describe the profiles obtained for each sample using the empirical equation shown below:
ெ
ெಮ

= ݇ ݐ

where

(2)

ܯ௧
ൗ ܯis the amount of drug released, k is the kinetic constant, t is the release time, and n
∞

is the diffusional exponent. Ritger and Peppas described controlled drug release from delivery
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vehicles of different classical geometries, emphasizing the importance of the exponent, n, on the
release behaviour.32-34 The authors summarized the results obtained for the values of the
diffusional exponent for release from non-swellable systems of different geometries (Table 3.3).
Table 3.3: Diffusional exponent and diffusion mechanism for non-swellable systems of
different geometries34
Diffusional exponent, n

Drug Release
Mechanism

Thin film

Cylindrical

Spherical

0.50

0.45

0.43

Fickian diffusion

0.50<n<1.0 0.45<n<1.0 0.43<n<1.0 non-Fickian transport
1.0

1.0

1.0

zero-order release

The values presented in Table 3.3 describe release behaviour with the assumption of onedimensional diffusion under perfect sink conditions. Also, the data presented by Ritger and
Peppas correspond to monodisperse samples. However, with the presence of a particle size
distribution, the expected values of n change. As described by Ritger and Peppas, the particle
size distribution causes a significant acceleration of diffusion earlier in the release profile and a
substantial retardation of release at longer times. Based on the work of Ritger and Peppas, it is
possible to determine whether the samples show Fickian or non-Fickian diffusion, however,
further release studies must be conducted before a conclusion can be made about whether release
is diffusion driven.

3.6.4

In vitro Cell Studies

Breast cancer cell lines MDA-MB-231 (231) and MDA-MB-468 (468) were selected as model
cancer cells for in vitro experiments as they are clinically relevant cell lines which are available
in the laboratory. Also, these cell lines have been used in other work involving folate
targeting.35,36 However, these previous reports suggest contradictory information regarding the
expression of the folate receptor by each cell line. For this reason, it was essential to determine
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which cell line overexpresses the folate receptor relative to the other using an antibody labeling
technique combined with flow cytometry. Figure 3.10 shows that 468 cells exhibit higher
expression of the folate receptor relative to 231 cells. Therefore, it was expected that 468 cells
would show higher particle uptake in future uptake experiments. Sample S2 and S2c along with
their folic acid conjugated counterparts (S2FA, and S2FAc) were selected for in vitro
experiments due to the relatively small size compared to other samples, and more sustained
release compared to sample S1c.
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Figure 3.10: Folate receptor expression in MDA-MB-231 and MDA-MB-468 cells
Next, the uptake of FITC-labeled particles into the 231 and 468 cells were investigated. As
shown in Figure 3.11, S2FA exhibited 3.2-fold greater uptake into 231 cells than S2. This might
be attributed to some folate receptor present on these 231 cells. The 468 cells, exhibited a higher
level of MNP uptake in general, but the uptake was 3.9-fold higher for S2FA than S2. Overall,
these results are consistent with the relative folate receptor expression on these cell lines but
indicate only a modest difference in folic acid mediated uptake between 231 and 468.
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Figure 3.11:: Uptake of samples S2 and S2FA by MDA
MDA-MB-231 and MDA-MB
MB-468 cells
Before conducting cytotoxicity experiments with curcumin
curcumin-loaded
loaded aggregates, a cell viability
assay was performed to determine at what concentrations the “free curcumin” was toxic to the
cells. As shown in Figure 3.12, curcumin was non
non-toxic to both cell lines at concentrations
concentrati
up to
approximately 26 μg/mL.
g/mL. Higher concentrations resulted in significant levels of toxicity.
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Figure 3.12: Free curcumin dose response curve
Based on these results, 231 and 468 cells were incubated with samples S2c and S2FAc at particle
concentrations corresponding to curcumin concentrations in the range of 0.52 – 260 μg/mL. As
shown in Figure 3.13, 231 cells treated with S2c were more resistant than 468 cells, which might
result from the 231 cells being a highly aggressive breast cancer cell line.37 It may also be related
to the lower uptake of MNP into these cells in general. At the highest concentration tested, 231
cells treated with S2FAc showed slightly higher cell death than those treated with S2c but this
difference was not statistically significant.
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Figure 3.13: Cytotoxicity of curcumin-loaded nanoaggregates on breast cancer cells
In terms of 468 cells, death resulting from treatment with both S2c and S2FAc treated cells was
very similar. This can be attributed to the general susceptibility of 468 to treatment, as well as
their increased uptake of the MNPs. It was demonstrated earlier that the encapsulation efficiency
of curcumin in S2FAc is less than half of that in S2c and as a result there is less drug present in
S2FAc. This means that for S2FAc to deliver the equivalent dose of drug as for S2c, more than
twice as many particles must be taken up by the cells. This may cancel to some extent the
increase in uptake mediated by the folate.
To demonstrate that the toxicity indeed arose from curcumin rather than the MNPs itself, the
toxicities of S2 and S2FA were evaluated in both 231 and 468 cells at the highest concentrations
used in the above studies. As shown in Figure 3.14, at a concentration of 1000 μg/mL for both
S2 and S2FA, 231 cells show no toxicity. In 468 cells, 1000 μg/mL of S2 shows slight cell death
attributed to the toxic cationic charge present on the particle surfaces which is taken up by cells,
however this cell death is decreased when folic acid is present (S2FA).This can be explained by
the masking of this cationic charge by folic acid making the particles less toxic to cells. At a
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concentration of 2000 μg/mL,
g/mL, more cell death was observed for both 231 and 468 cells when
treated with sample
le S2, but this level of cell death was less than that observed in the above
studies with the curcumin-loaded
loaded particles, particularly for the FA
FA-conjugated
conjugated materials.
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Figure 3.14:: Cytotoxicity of samples S
S2 and S2FA

3.7

Conclusion

This chapter described the synthesis, characterization, and in vitro behavior of surface coated
magnetite nanoparticles. Magnetic iron oxide nanoparticles were surface coated to incorporate a
targeting ligand (folic acid) and a chemo
chemotherapeutic
therapeutic agent (curcumin). Nanoparticles were 10 –
20 nm in size as measured by DLS and were noted to form aggregates of a few hundred
nanometers to microns. It was demonstrated that this aggregation decreased with increasing
amounts of PPG-NH2, however sample S2 deviated from this trend, showing the smallest
aggregate size. FTIR analysis confirmed the presence of folic acid on the nanoparticles surfaces
to serve as a targeting ligand for the folate receptor which is overexpressed on cancer cells
surfaces.
s. Furthermore, magnetization studies revealed that nanoaggregates retained their
magnetic properties even after coating of the iron oxide core, which is required for the desired
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application. In vitro curcumin release studies carried out on samples S1c and S2c, along with
their folic acid-conjugated counterparts (S1FAc and S2FAc, respectively) demonstrated
sustained release, over varying time periods. Sample S2c showed the best results in terms of
controlled release, lasting for 11 days. However, sample S2FAc showed a higher burst effect
than sample S2c suggesting that curcumin may have been only loosely encapsulated in sample
S2FAc. Samples S1c and S1FAc showed similar release profiles, both demonstrating high burst
effects and release lasting for approximately 3 days. Based on the release studies results, in vitro
cell studies were carried out using samples S2 and S2FA on breast cancer cell lines MDA-MB231 and MDA-MB-468. It was demonstrated that 468 cells are folate positive relative to 231
cells, and as a results, 468 cells showed higher folate-mediated uptake of nanoparticles as
compared to 231 cells. Cytotoxicity studies showed higher susceptibility of 468 cells to curcumin
compared to 231 cells. Also, 468 cells treated with samples S2c and S2FAc showed similar cell
viability, likely because S2FAc holds approximately half the amount of drug as S2c, meaning
that approximately twice the amount of S2FAc is required to deliver the same amount of
curcumin as sample S2. However, the flow cytometry results still confirm that the selective
targeting by folic acid in sample S2FA, suggesting that this might be translated to an effect in
vivo, under non-static conditions. Therefore, the results obtained support the notion that
magnetite nanoparticles conjugated with folic acid can potentially be used for the controlled
delivery of curcumin for potential chemotherapeutic applications.
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Chapter 4
4

Conclusions and Future Prospects

To reduce the side effects induced by traditional chemotherapy, this thesis demonstrated a
potential means of targeted delivery for a natural chemotherapeutic agent. Specifically, magnetic
magnetite nanoparticles were synthesized through a simple method, conjugated with folic acid
for ligand targeted treatment, and loaded with curcumin as a chemotherapeutic agent. An
extensive review was presented in Chapter 2 on the chemical properties of curcumin, its
biological activity/mechanisms of action as an anti-cancer agent, and previous approaches to its
delivery.
Chapter 3 described the experimental methods, results, and discussion. Synthesized magnetite
nanoparticles coated with β-cyclodextrin (β-CD) and poly(propylene glycol) bis (2-aminopropyl
ether) (PPG-NH2) were characterized using various techniques, which revealed that
nanoparticles were 10 – 20 nm in size and formed micron-sized aggregates. XRD analysis
ensured that the synthesized iron oxide samples were in fact magnetite, and magnetic studies of
both coated and uncoated particles showed that the samples retained their magnetic properties,
even after the magnetite core was coated. FTIR spectra ensured the presence of both coating
agents on the surface, and the successful conjugation of folic acid to PPG-NH2.
In vitro drug release studies were conducted in buffer in order to determine the rate of curcumin
release. S2c containing more PPG-NH2, and S1c were investigated for sustained curcumin
release and it was determined that S2c showed significantly better controlled release, lasting for
11 days. The presence of PPG-NH2 likely increased the hydrophobic interactions, which must be
broken for curcumin diffusion. However, for sample S2FAc the release of curcumin was faster,
which was attributed to the presence of folic acid before curcumin loading, potentially making it
difficult for curcumin to be entrapped securely in the β-CD cavities. Samples S1 and S1FA
showed similar release profiles with high burst effects lasting for approximately 3 days. Based
on these results, it may be possible to determine an optimum amount of PPG-NH2for folic acid
conjugation which will demonstrate the most controlled curcumin release.
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Sample S2 along with its folic acid conjugated (S2FA) and curcumin loaded counterparts (S2c
and S2FAc) were chosen for in vitro experiments conducted on MDA-MB-231 (231) and MDAMB-468 (468)breast cancer cells. It was demonstrated that 468 cells are folate receptor positive
compared to 231 cells, and this was supported by the ligand-mediated uptake of folic acidlabeled magnetite samples (S2FA) by 468 cells compared to the relatively little uptake shown by
231 cells. In vitro cytotoxicity studies were carried out on samples S2c and S2FAc. The results
demonstrated more cell death in 468 cells than 231 cells, as 231 cells were relatively folate
negative and are a more treatment-resistant cell line. In addition, the amount of curcumin in
folate-labeled nanoaggregates is approximately half of that present in non-labeled
nanoaggregates which was why 468 cells showed similar cell death for both folic acid-labeled
and non-labeled samples. In general, curcumin delivered by nanoaggregates is more toxic to 468
cells than 231 cells.
With the promising results obtained by these studies, it would be interesting to evaluate these
systems in vivo and to investigate the effects of magnetic targeting in the enhancement of
cytotoxicity in the future. Also, it would be beneficial to track these nanovehicles using MRI
while simultaneously acting as a chemotherapeutic agent. In order to achieve this, it would also
be ideal to reduce the degree of aggregation of the particles under physiological conditions so
that they can be administered intravascularly and can exhibit prolonged circulation in the blood.
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Appendix
Appendix 1: Standard XRD pattern for magnetite corresponding to ICCD card number
00-019-0629
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Appendix 2: 1H NMR spectra of curcumin and β-cyclodextrin

Curcumin
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β-cyclodextrin
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Appendix 3: H1 NMR of β-CD/curcumin Complex in Water
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Appendix 4: H1 NMR of β-CD/curcumin Complex in Acetone
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